Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib Authors: Muhammad Latif, Sana Mazhar, Mussarat Tasleem, Abdulmajeed Alqurashi, Muhammad Arfan, Zaman Ashraf, Muhammad Sohail Zafar Published: 2026 ABSTRACT AbstractPoly(ADP-ribose) polymerase (PARP) inhibition has emerged as a prominent approach in cancer treatment, leading to the development of several poly(ADP-ribose) polymerase inhibitors (PARPi), which have demonstrated substantial progress in clinical trials and efficacy in the management of ovarian cancer (OC), breast cancer (BC), and solid tumors (STs). These PARPi are approved for several cancers, including BC and OC. Among PARPi, Talazoparib (Talzenna®) is a potent therapy for patients with locally advanced or metastatic BC (mBC) with germline BRCA mutations (gBRCAm) and HER2-negative status, demonstrating the highest potency (IC50 = 0.57 nM), which is 4–10 times lower than that of other PARP inhibitors; olaparib (2.0 nM), rucaparib (1.9 nM), and veliparib (4.7 nM), indicating superior efficacy. This review describes the role of BRCA1/2 in BC and OC, highlighting key discovery milestones and providing an overview of available PARP inhibitors (PARPi) at various stages of development. Additionally, it details the discovery and development of talazoparib, one of the key PARPis, its current clinical status, and therapeutic implications. The latest advancements in talazoparib research, including all related clinical trials (Phase 1–3) for the treatment of BC, OC, and other solid tumors (STs), are also summarized. A comprehensive analysis of all clinical trials involving talazoparib, whether as monotherapy or in combination with other drugs, elucidates its potential to improve clinical outcomes, address drug resistance, and explore synergistic combinations with other PARPi or novel agents, thereby providing insights into the clinical utility of talazoparib. Introduction Cancer continues to represent a significant global health challenge, contributing to millions of new diagnoses and fatalities annually. Recent global estimates reveal that nearly 20 million new cancer cases and approximately 9.7 million deaths were recorded worldwide in 2022, underscoring the increasing burden of malignancies in both developed and developing regions.1–3 Among these, solid tumors (STs) account for the majority of global cancer cases, with lung, breast, colorectal, and prostate cancers being the most frequently diagnosed malignancies. BC and OC collectively contribute significantly to the global burden of solid tumors, which account for over 90% of all newly diagnosed cancer cases worldwide. According to the GLOBOCAN 2022 global estimates, female breast cancer remains the most prevalent malignancy among women, with an estimated 2.30 million new cases in 2022 and an age-standardized incidence rate (ASR) of approximately 46.8 per 100,000 population.1,4 This reflects substantial regional disparities, with higher ASRs in developed regions such as Northern America and Europe compared to lower rates in parts of Asia and Africa. In the same year, OC accounted for approximately 324,603 new cases globally, with an ASR of 6.7 per 100,000, ranking among the top ten cancers in women by incidence. STs overall—including breast, lung, colorectal, prostate, and stomach cancers—constituted the vast majority of cancer incidence, with approximately 19.98 million new cases worldwide. The combined age-standardized rates for all cancers (excluding non-melanoma skin cancer) were approximately 186.5 per 100,000 across both sexes, underscoring the dominant contribution of solid malignancies to global cancer incidence and highlighting the need for continued emphasis on solid tumor epidemiology in research and healthcare planning.4–6 The prevalence of cancer has risen dramatically in countries with low and middle incomes, and this pattern is anticipated to persist, as economic growth leads to lifestyle changes that elevate women’s risk of disease in these nations. Furthermore, low- and middle-income ‎nations lack financial resources to provide extensive technology-driven healthcare to their citizens. In wealthy countries, the anticipated cost of medical treatment has escalated rapidly.7 The mortality rate is consistently declining, particularly among younger female patients, owing to advancements in treatment and earlier detection methods.8 The prognosis of patients with BC varies significantly based on factors such as the stage at diagnosis, molecular subtype, and other clinical and pathological features. Among these factors, the stage at which the cancer is detected is the most robust predictor of survival. The 5-year relative survival rate demonstrates a marked contrast across different stages: it exceeds 99% for cancer diagnosed at a localized stage, decreases to 87% for regional stage disease, and declines further to 32% for cases which cancer has metastasized to reserved parts of the body. Over the past two decades, BC survival rates have improved remarkably.9 The lifetime risk of BC or OC is greatly amplified if a woman inherits a mutation in BRCA1 or BRCA2 genes. A positive family history of BC is a significant risk factor for the development of this type of cancer. After an individual’s age, family history is considered the most established factor contributing to an increased risk.10 According to current scientific understanding, hereditary cancer susceptibility syndromes resulting from high-penetrance gene mutations are account for almost 5% of all BC cases. A substantial proportion of hereditary BC, approximately 50%, is linked with the germline mutations in the BRCA1/2 genes.11,12 A literature search was conducted to gather publications related to the subject matter. Major scientific databases, including PubMed, Scopus, Web of Science, ScienceDirect, Google Scholar, and the Food and Drug Administration website, were utilized to ensure comprehensive coverage of the available literature. The search employed various combinations of predefined keywords and Boolean operators pertinent to the research topic. Only peer-reviewed articles published in reputable journals were considered. Additionally, the reference lists of selected articles were manually screened to identify further relevant studies. The retrieved literature was critically evaluated and curated to provide an up-to-date and comprehensive synthesis of current developments in the field. The data searches were restricted to peer-reviewed articles published in English. Recent studies were prioritized to incorporate the most up-to-date findings, while earlier publications were also included when pertinent to the conceptual framework of the field, thereby providing a comprehensive dataset focused on talazoparib. This review describes the role of BRCA1/2 in BC and OC, highlighting key discovery milestones and providing an overview of available PARP inhibitors (PARPi) at various stages of development. Additionally, it details the discovery and development of talazoparib, one of the key PARPis, its current clinical status, and its therapeutic implications. We summarize the latest advancements in talazoparib research, including all related clinical trials (Phase 1–3) for the treatment of BC, OC, and STs, are summarized. A comprehensive analysis of all clinical trials involving talazoparib, whether as monotherapy or in combination with other drugs, elucidates its potential to improve clinical outcomes, address drug resistance, and explore synergistic combinations with other PARPi or novel agents, thereby providing insights into the clinical utility of talazoparib. Discovery and Structure of BRCA1/2 BRCA1/2 genes were identified in the 1990s. BRCA1 was initially associated with BC in 1990 through linkage analysis of a large group of families with early onset of BC and was found to be localized to chromosome 17q21.13 BRCA1 was subsequently cloned in 1994, with truncating mutations found in its coding sequence in families with multiple BC cases.14 The quest for additional genes potentially involved in hereditary BC susceptibility resulted in the discovery of BRCA2 in 1995, which is located on chromosome 13q12.3. Researchers have discovered BRCA2 through the application of linkage analysis and positional cloning techniques to multigenerational familial BC pedigrees.15,16 Simultaneously, various families exhibiting high rates of male BC have been found to carry BRCA2 mutations.17 Multiple studies have shown that individuals with BRCA1/2 mutations not only have BC and OC but also face enhanced risks of malignancies in the fallopian tubes, colon, prostate, skin (melanoma), and pancreas.18–24 BRCA1/2 genes possess intricate genomic structures and are essential for DNA repair mechanisms; they create complexes that assist in repairing double-strand breaks (DSBs) and trigger homologous recombination (HR).25,26 Cells lacking functional BRCA1 and BRCA2 show increased vulnerability to DSB-inducing agents such as mitomycin C and cisplatin.27–29 Additionally, ionizing radiation causes these breaks, which are repaired using error-prone methods, such as non-homologous end-joining.30,31 Individuals with BRCA1/2 gene mutations have a high lifetime risk of developing BC ranging from 60% to 85%. These mutations also increase the lifetime risk of OC, with BRCA1 carriers having a 26% to 54% risk and BRCA2 mutation carriers having a 10% to 23% risk. BRCA1/2 gene mutations are responsible for approximately 45% of families with multiple BC cases and up to 90% of families with both BC and OC.32–35 Importantly, hereditary BC associated with BRCA1 or BRCA2 mutations exhibits both unique clinical and pathological features.36–38 Poly (ADP-Ribose) Polymerases and BRCA1/2 Poly (ADP-ribose) polymerases (PARPs) constitute a family of enzymes capable of facilitating the transfer of ADP-ribose to target proteins through a process known as poly ADP-ribosylation (pADPr‎). This family is comprised of at least 17 members (with only 10 putative), each encoded by distinct genes and sharing homology in a conserved catalytic domain. While PARP1 and PARP2 are predominantly associated with DNA repair functions, investigations have demonstrated that these and other PARP isoforms are crucial for numerous cellular processes, including regulation of cell proliferation and programmed cell death. Researchers have identified numerous cellular substrates of PARP, with the majority comprising proteins localized in the nucleus that are involved in nucleic acid metabolism, DNA synthesis and repair, and modification of chromatin structure. Upon the occurrence of DNA strand breaks, PARP undergoes self-modification and functions as one of the primary acceptors of poly-ADP ribose in biological systems and in vivo models. PARP1 is considered a first-in-class and the most thoroughly investigated key member of the PARP family and is closely related to PARP2. The latter shares 69% similarity in its catalytic domain with PARP1 and was found because of the persistence of PARP potential in cells lacking PARP1. As mentioned above, the most prevalent form of PARP-1 is crucial in repairing DNA single-strand breaks via the base excision repair Pathway.39 PARP1 also modifies BRCA1 with pADPr, influencing DSB repair during HR40 and hindering non-homologous end-joining (NHEJ) repair by preventing Ku protein attachment to DNA ends.41,42 Moreover, PARP1 is essential for other microhomology-mediated end-joining repair pathways.43,44 It is noteworthy that both PARP2 and PARP3 also aid in DNA repair; PARP2 works alongside PARP1 in pADPr synthesis, whereas PARP3 suppresses error-prone NHEJ.45–47 The inhibition of PARP enzymes results in the accumulation of single-strand breaks in the DNA. This accumulation subsequently leads to the formation of DSBs at sites of DNA replication. In normal cells, these DSBs are primarily repaired by the error-free HR pathway, which relies on the BRCA1 and BRCA2 tumor suppressor proteins. In the absence of BRCA1 or BRCA2, this damage remains unrepaired, causing cell cycle arrest and death, despite the alternative NHEJ pathway for DSB repair. Some authors have elucidated the significance of PARP in DNA repair mechanisms and the fundamental actions of PARP inhibitors.48 The Discovery Journey of PARP1/2 Inhibitors The discovery and development of several key PARPi as anti-tumor agents have demonstrated their efficacy and effectiveness in both in vitro and in vivo models. It has been shown that under the concept of synthetic lethality, PARPi can be employed as a monotherapy agent; however, their use in combination with chemotherapy or radiotherapy to induce a synergistic effect is another therapeutic arena. The translation of this biological concept, termed synthetic lethality, into a clinically oriented practice has been objectified by PARPs. It is an imperial illustration of translational medicine. The basic mechanistic pathway of PARP inhibition is shown in Figure 1, and the milestones in the discovery of clinically relevant PARPi developed from the nicotinamide pharmacophore are shown in Figure 2. Figure 1The basic mechanistic pathway of PARP inhibitors.A 2D line-bond chemical scheme showing NAD plus on the left, a reaction arrow labeled PARPi pointing to the right and a separate small molecule labeled 3-AB on the far right with IC subscript 50 equals 10 micromolar. Left structure: NAD plus is written near the top. Below the left portion, the label ADP ribose appears. The leftmost part contains a fused bicyclic base drawn with multiple double bonds and several N labels and an NH subscript 2 substituent. This base is connected to a five-membered sugar ring drawn with an internal O and two OH labels at the top. From that sugar, an O linker connects to a chain of two phosphate groups drawn as P atoms with multiple O atoms, including O minus markings and an OH on one phosphate. The phosphate chain connects through an O to a second five-membered sugar ring drawn with an internal O and two OH labels at the bottom. Highlighted group: Attached to the second sugar ring is a six-membered aromatic ring drawn with alternating double bonds and one N label in the ring. This ring is enclosed by a dashed oval and labeled Nicotinamide moiety. From the ring, a substituent is drawn as C double bond O connected to N H, with the N bearing two H labels. Cleavage annotation: Blue text reads Cleavage of bond by PARPi, with a blue dashed arrow pointing to the bond between the second sugar ring and the highlighted six-membered ring. Right structure: 3-AB is drawn as a six-membered aromatic ring with alternating double bonds, bearing a C double bond O connected to N H subscript 2 substituent and a separate NH subscript 2 substituent on the ring.2D line-bond scheme of NAD plus cleavage by PARPi, highlighting nicotinamide and 3-AB. Figure 2The discovery milestone of PARPi containing a nicotinamide pharmacophore for the treatment of BC, OC, and STs.A two-column vertical timeline infographic listing milestones for PARPi. Reading order: the first column runs from 1963 to 2016 and the second column runs from 2017 to 2024. Each entry has a year label and a chevron marker pointing to a text box. 1963: Detection of poly (ADP-ribose) 1977: Purification of PARP-1 1980: Role of nuclear PARPi in DNA damage repair and discovery of novel inhibitors 1984: HER2 gene was identified 1985: HER2 amplification was described in breast cancer 1987: Cloning of the PARP-1 gene 1992: Herceptin development was published 1994: BARCA -1 was isolated 1995: BARCA -2 was isolated 2005: Preclinical data, PARP inhibition caused synthetic lethality in BRCA1/2-mutated cells 2007: Lapatinib development for the treatment of metastatic HER2 and BC 2009-2013: Olaparib (LYNPARZA®) phase I-III 2014: FDA approval of olaparib for BRCA1/2 mutants. Veliparib was studied in Phase III trials for OC, TNBC and NSCLC 2016: The FDA granted accelerated approval of rucaparib (rubraca®) for ovarian cancer. The FDA approved olaparib for prostate cancer (BRCA mutant) 2017: Niraparib (zejula®) was approved as the first PARPi and introduced for the maintenance of BRCA mutants 2017: Launch of first-in-class olaparib in 2nd-line metastatic setting in patients with BRCA1/2 mutations (maintenance of BRCA mutants) 2017: Veliparib failed to improve outcomes in TNBC and NSCLC trials 2018: The FDA granted approval of rucaparib for the maintenance of BRCA-mutants 2018: Talazoparib (talzenna®) and niraparib (launch of talazoparib and niraparib in the second-line metastatic settings in patients with BRCA1/2 mutations) 2018: Talazoparib got approval from the FDA for gBRCAm HER2-negative locally advanced or metastatic BC 2019: Administration of the first PARP-based combination was recommended. Launch of veliparib in combination with taxane in the first-line metastatic setting in patients with BRCA 1/2 mutant 2019: Niraparib was approved for HRR-deficient tumors 2020: Niraparib was used for maintenance regardless of HRR status 2020: Olaparib was launched in an early disease setting of chemotherapy induction in patients with BRCA1/2 mutations. Olaparib was administered in combination with bevacizumab (avastin®) in HRR-deficient patients 2021: Pamiparib (partruvix®) was approved for BRCA1/2 mutants 2023: The FDA approved the combination of talazoparib with enzalutamide (1:1) for HRR-mutated mCRPC upon priority review 2024: Talazoparib was licensed in Europe and approved by the European Commission as the first PARP inhibitor. A combination of talazoparib with enzalutamide (xtandi®) to treat adults with mCRPC 2024: A combination of olaparib with abiraterone (zytiga, yonsa) got FDA approval for the treatment of patients suffering from BRCA-mutated mCRPC.A two-column timeline infographic of PARPi discovery and approval milestones from 1963 to 2024. The basic mechanistic pathway of PARP inhibitors. The discovery milestone of PARPi containing a nicotinamide pharmacophore for the treatment of BC, OC, and STs. Poly (ADP-ribose) polymerase inhibitors (PARPi) are synthetic molecules that disrupt the capacity of cells to repair their DNA. Mutations in the BRCA1/2 genes are responsible for 5–10% of all BC cases. Studies have demonstrated that cancers associated with BRCA1/2 mutations exhibit increased susceptibility to PARPi. PARP1/2 inhibitors have emerged as an inspiring class of anti-cancer agents, and many PARP1/2 inhibitors have been reported. Several small molecules targeting PARP have been synthesized and developed as DNA-damaging chemotherapeutic agents or chemosensitizers in conjugation with ionizing radiation (especially for BRCA1/2 mutant BC or OC).45,49 To date, many PARPi have been identified, most of which are nicotinamide analogs.50–53 Most PARPi are in Phase II and III (late phase) clinical therapeutic trials, including rucaparib (AG-014699),54,55 olaparib (AZD-2281),56 veliparib (ABT-888),57–59 niraparib (MK-4827, Zejula®)60,61 and talazoparib (BMN 673).62 Among nicotinamide analogs, talazoparib (BMN 673) is a novel, orally bioavailable, dual-mechanism PARPi that effectively traps PARP in DNA. Most PARP1 inhibitors developed to date are nicotinamide mimetics (NAMs). This structural mimic of nicotinamide allows PARP1 inhibitors to support favorable binding to the enzyme. Figures 3 and 4 show the first and 2nd-generation PARPi, which were based on the i)-nicotinamide core, ii)-benzamide motif, and iii)-substituted benzamides, such as 3-aminobenzamide (3-AB). Nicotinamide, a weak PARP inhibitor, was discovered in 1971, wherein 5′-methyl nicotinamide and nicotinamide were investigated as inhibitors of poly ADP-ribose polymerase and nicotinamide adenine dinucleotide (NAD) nucleosidase.63 Since 1980, discovery efforts have made the nicotinamide core a key motif in first-generation PARPi, and 3-AB was developed as the first widely investigated agent.64 Currently, there are at least nine PARPi in clinical development (Table 1). Table 1A Summary of the Key PARPi Currently Undergoing Clinical TrialsName/StructurePhase, Company, Therapy Type, Indication at Present/Tumor TypeA benzene ring with iodine, nitro and amide substituents.Iniparib (BSI 201) BiPar/SanofiBipar Sciences developed this molecule. Research conducted by BiPar/Sanofi indicates that Iniparib lacks the typical characteristics of PARP inhibitors. In addition to BC, NSCLC is another relevant condition and is administered intravenously. The combination of Iniparib with carboplatin and gemcitabine demonstrated significant efficacy in treating mTNBC. A randomized phase II trial (NCT01045304) in 2011 evaluated the efficacy of carboplatin and gemcitabine, with or without Iniparib, in TNBC patients who had received up to two prior chemotherapy regimens for metastatic disease. Information on BRCA status was not provided.65 In Phase III (NCT00938652), Iniparib exhibited improved progression-free survival (5.1 months) and overall survival (11.8 months).66A compound with two benzene rings, a piperazine ring and a cyclopropane group.Olaparib (AZD2281) AstraZenecaAstraZeneca developed this compound, which is currently progressing in Phase II (single agent) and Phase III (combination) clinical trials. Olaparib, an orally administered PARP inhibitor, exhibits superior efficacy compared to conventional treatments in HER-negative mBC and gBRCAm BC patients. Investigations have explored its potential in various conditions, including BC, OC, colorectal, fallopian tube, breast, lung, prostate, pancreatic, gastric, and advanced tumors. The drug is utilized as both monotherapy and in combination regimens, demonstrating promising results in treating TNBC patients. When combined with radiotherapy, olaparib was well-tolerated in TNBC cases67 and may function as an effective radiosensitizer for this subtype of BC.68Skeletal formula with pyrrolidine, fused diazine-benzene and carboxamide group.Veliparib (ABTT888) AbbottThis molecule was developed by Abbott and currently undergoing Phase II clinical trials (monotherapy or combination). It is an orally available agent. Other targets are melanoma, fallopian tube, peritoneal, BC, OC, peritoneal, lung, colorectal, cervical, prostate, glioblastoma pancreatic, and advanced tumors. In Phase III (combination therapy), BC, lung cancer, and glioblastoma are among other targets.Line angle structure of a fused ring lactam linked to a sulfonamide and an R defined morpholine chain.INO-1001 Inotek/GenentechThis is an early-stage PARPi named INO-1001, which was developed by Inotek/Genentech but discontinued after the outcome of Phase 1 clinical trials.69 This compound exhibited potent PARP1/2 binding and demonstrated notable selectivity of PARP1 over PARP2. INO-1001 showed almost 30-fold more selectivity (PARP1/PARP2; 7.9 vs 217.2 nM). The selectivity profile of INO-1001 was comparable to that of niraparib, potentially owing to the structural similarities, although direct comparisons of their PARP binding mechanisms are not available. Significantly, the DLT observed with this small molecule was hematological in nature. These toxicities were retrospectively attributed to the PARP2 inhibition. The rationale for halting clinical development remains unclear because no serious AEs were reported in the Phase 1 trials. The pharmacokinetic data displayed by INO-1001 were encouraging. However, concerns regarding potential hepatotoxicity might have influenced this decision.70,71Skeletal formula of a fused aromatic system with fluorine, carbonyl and bicyclic side chain with nitrogen.Primapraib (BGB-290) BeiGeneThis molecule is currently progressing in Phase II clinical trials (NCT03427814). BeiGene, a company based in Beijing, China, has developed pamiparib (BGB-290) and is currently progressing multiple phase II/III clinical trials. This substance, characterized as a fused pentacyclic dihydrodiazepinoindolone derivative, demonstrates significant efficacy against both PARP-1 and PARP-2 enzymes, with IC50 values of 1.3 and 0.9 nM, respectively. Furthermore, pamiparib exhibits substantial selectivity when compared to TNKS1 and TNKS-2, with IC50 values of 230 and 140 nM, respectively.722D skeletal formula with 2 carbonyls, CF3 group, F substituted benzene and multiple N atoms.Fluzopraib (SHR-3162) Jiangsu HengRui MedicineJiangsu HengRui Medicine Co., Ltd, China, is currently developing Fluzoparib. The compound is progressing in Phase II clinical trials (NCT05732129, not currently recruiting). Furthermore, a Phase 1 trial (NCT03509636) is in progress for patients with BRCA1/2-mutant OC. In a Phase I study, Fluzoparib, a PARP inhibitor, exhibited promising anti-tumor effects in advanced OC cases. This agent, also known as SHR3162 or HS10160, is an oral and highly potent PARP inhibitor that demonstrates anti-tumor properties, with a PARP1 IC50 of 1.46±0.72 nM.73,74A 2D skeletal formula of a fused bicyclic ring with C double bond O, N H, ethoxy and morpholine.Amelpraib (JPI-289) Jeil PharmaceuticalsThis molecule was developed by Jeil Pharmaceuticals, Korea. It is presently enduring Phase II clinical Trials (CT03062397). JPI-289, or Amelparib (free base), is a highly potent, orally available, and water-soluble PARP-1 inhibitor. This compound demonstrates nanomolar-range inhibition of PARP-1 (IC50=18.5 nM) and cellular PAR formation (IC50=10.6 nM). Amelparib shows promise as a neuroprotective agent and may have applications in acute ischemic stroke research. The substance exhibits promising potential as a neuroprotective agent in acute ischemic stroke; however, it has not demonstrated efficacy for acute kidney injury resulting from ischemia and has shown a negative impact on healing.75Tricyclic heteroaromatic with carbonyl, 3 ring nitrogens and fused indane side chain.Stenoparib (E7449, 2X-121, MGI25036)Allarity Therapeutics, a US-based company, is currently advancing this compound through Phase II clinical trials (NCT03562832). Stenoparib (E7449, 2X-121, MGI25036) is characterized as an orally administered, brain-penetrating small molecule that functions as a dual inhibitor of PARP1/2. This compound also demonstrates inhibitory effects on PARP5a/5b and possesses a unique dual-inhibitory mechanism targeting both PARP 1/2 and Tankyrase 1/2 (TNKS1/2), the latter being a crucial regulator of canonical Wnt/β-catenin signaling. The agent exhibits promising PARP inhibition (PARP1; C50=1.0 nM, and PARP2; IC50=1.2 nM). Additionally, the molecule shows efficacy in P-glycoprotein-expressing cells, indicating its potential to overcome certain forms of PARP inhibitor resistance.Line-angle skeletal formula of a fused bicyclic system with F, C double bond O and two NH groups.Rucaparib (Rubraca, AG014699, PF01367338)This molecule was developed by Pharmaand GmbH, Germany. At present, Phase III clinical trials are in evolution for rucaparib. In a cell-free assay, rucaparib phosphate demonstrates inhibition of PARP1 (Ki=1.4 nM) and exhibits binding affinity to a further 8 additional PARP domains (NCT04539327). It is the first PARP inhibitor utilized in clinical trials in combination with TMZ. This compound is under development for the therapy of OC associated with HR DNA repair deficiency (HRD) and is presently continuing in Phase 1/2 clinical trials (NCT01482715). Furthermore, investigators have assessed the safety as well as efficacy of rucaparib in individuals with relapsed OC harboring BRCA mutations.76Line-angle formula of fused rings linked to phenyl and cyclohexane, with H subscript 2 N C double bond O.Nirapraib (MK-4827) MerckThis molecule was developed by Merck. Niraparib, a PARP inhibitor, has received FDA consent to treat platinum-sensitive ovarian serous carcinoma. Phase III clinical trials have established its safety profile. This compound demonstrates selectivity for PARP inhibition (PARP1, IC50=3.8 nM and PARP2, IC50 = 2.1 nM) and demonstrates significant efficacy in cancer cells with BRCA1 and BRCA2 mutations. It exhibits greater than 330-fold selectivity against V-PARP, PARP3 and Tank1. Through the formation of PARP–DNA complexes, niraparib induces DNA damage, apoptosis, and cell death. At present, several clinical trials are investigating niraparib’s therapeutic potential for serous endometrial carcinoma (NCT05289648, Early Phase 1, Not yet recruiting). Monotherapy and a combination of niraparib and GSK4524101 for STs has also been evaluated (NCT06077877).Two dimensional skeletal structure with fused rings, two carbonyls, an O substituent and a piperazine.CEP-9722, proagent of CEP-8983, (Teva)CEP-9722, which functions as the proagent for CEP-8983, is a potent and orally administered inhibitor that specifically targets PARP-1 and PARP-2, with IC50 values of 20 nM and 6 nM, respectively. This compound exhibits anticancer properties and is at this time undergoing evaluation in Phase 1/2 Clinical trials (NCT01311713) under the supervision of Teva Branded Pharmaceutical Products R&D, Inc. The primary objective of these studies is to regulate the maximum tolerated dose that can be safely administered on a daily basis to patients with advanced or metastatic STs, as well as to measure the tolerability and safety of this established dose.A two-dimensional line-bond formula of a fused bicyclic ring linked to piperazine and an amide.AZD9574AZD9574 is a newly developed brain-penetrant compound with a distinct structural framework. It acts as a PARP inhibitor and demonstrates exceptional PARP1 selectivity (>8000-fold selectivity for PARP1 over PARP2), trapping ability, and enhanced CNS penetration within a single molecule. This compound exhibits PARP1 IC50 in the range between 0.3–2 nM. Experimental data from animal studies supports its advancement as a promising next-generation therapeutic candidate for addressing metastatic diseases and primary brain tumors. Thus, for patients with HRD+ BC that has metastasized to the brain, AZD9574 represents a potentially efficacious therapeutic intervention.77 Figure 3Core structure of first-generation PARP inhibitors.The image shows two chemical structures. The first structure is labeled 'Amide' with an IC50 value of 210 micromolar. It consists of a six-membered ring with five carbon atoms and one nitrogen atom. Attached to the nitrogen atom is a carbonyl group (C double bond O) linked to an NH2 group. The second structure is labeled '3-aminobenzamide' with an IC50 value of 33 micromolar. It features a benzene ring with an NH2 group attached to the third carbon. A carbonyl group (C double bond O) is connected to an NH2 group, attached to the benzene ring. Both structures are depicted in blue.Structures of amide and 3-aminobenzamide with IC50 values. Figure 4Structural characteristics of selected second-generation PARP inhibitors.Chemical structures with potency data: PD128763: bicyclic with benzene and carbonyl, IC50 420 nM. NU1025: similar structure with hydroxyl, IC50 400 nM, Ki 48 nM. DPQ: benzene linked to carbonyl and NH, IC50 1 µM. Iniparib (BSI-201): benzene with carbonyl, NH2, nitro, iodine, IC50 30 µM, initially PARPi but disproven. 4-ANI: bicyclic with two carbonyls, NH2, IC50 180 nM. ISO: bicyclic with carbonyl, hydroxyl, IC50 390 µM. PJ-34: bicyclic with carbonyl, amide chain, IC50 20 nM. E7016, GP121016: polycyclic with benzene, carbonyl, NH, hydroxyl, no IC50 or Ki values.2D skeletal structures of 8 PARP inhibitors with IC50 and Ki potency labels. Table 1A Summary of the Key PARPi Currently Undergoing Clinical TrialsName/StructurePhase, Company, Therapy Type, Indication at Present/Tumor TypeA benzene ring with iodine, nitro and amide substituents.Iniparib (BSI 201) BiPar/SanofiBipar Sciences developed this molecule. Research conducted by BiPar/Sanofi indicates that Iniparib lacks the typical characteristics of PARP inhibitors. In addition to BC, NSCLC is another relevant condition and is administered intravenously. The combination of Iniparib with carboplatin and gemcitabine demonstrated significant efficacy in treating mTNBC. A randomized phase II trial (NCT01045304) in 2011 evaluated the efficacy of carboplatin and gemcitabine, with or without Iniparib, in TNBC patients who had received up to two prior chemotherapy regimens for metastatic disease. Information on BRCA status was not provided.65 In Phase III (NCT00938652), Iniparib exhibited improved progression-free survival (5.1 months) and overall survival (11.8 months).66A compound with two benzene rings, a piperazine ring and a cyclopropane group.Olaparib (AZD2281) AstraZenecaAstraZeneca developed this compound, which is currently progressing in Phase II (single agent) and Phase III (combination) clinical trials. Olaparib, an orally administered PARP inhibitor, exhibits superior efficacy compared to conventional treatments in HER-negative mBC and gBRCAm BC patients. Investigations have explored its potential in various conditions, including BC, OC, colorectal, fallopian tube, breast, lung, prostate, pancreatic, gastric, and advanced tumors. The drug is utilized as both monotherapy and in combination regimens, demonstrating promising results in treating TNBC patients. When combined with radiotherapy, olaparib was well-tolerated in TNBC cases67 and may function as an effective radiosensitizer for this subtype of BC.68Skeletal formula with pyrrolidine, fused diazine-benzene and carboxamide group.Veliparib (ABTT888) AbbottThis molecule was developed by Abbott and currently undergoing Phase II clinical trials (monotherapy or combination). It is an orally available agent. Other targets are melanoma, fallopian tube, peritoneal, BC, OC, peritoneal, lung, colorectal, cervical, prostate, glioblastoma pancreatic, and advanced tumors. In Phase III (combination therapy), BC, lung cancer, and glioblastoma are among other targets.Line angle structure of a fused ring lactam linked to a sulfonamide and an R defined morpholine chain.INO-1001 Inotek/GenentechThis is an early-stage PARPi named INO-1001, which was developed by Inotek/Genentech but discontinued after the outcome of Phase 1 clinical trials.69 This compound exhibited potent PARP1/2 binding and demonstrated notable selectivity of PARP1 over PARP2. INO-1001 showed almost 30-fold more selectivity (PARP1/PARP2; 7.9 vs 217.2 nM). The selectivity profile of INO-1001 was comparable to that of niraparib, potentially owing to the structural similarities, although direct comparisons of their PARP binding mechanisms are not available. Significantly, the DLT observed with this small molecule was hematological in nature. These toxicities were retrospectively attributed to the PARP2 inhibition. The rationale for halting clinical development remains unclear because no serious AEs were reported in the Phase 1 trials. The pharmacokinetic data displayed by INO-1001 were encouraging. However, concerns regarding potential hepatotoxicity might have influenced this decision.70,71Skeletal formula of a fused aromatic system with fluorine, carbonyl and bicyclic side chain with nitrogen.Primapraib (BGB-290) BeiGeneThis molecule is currently progressing in Phase II clinical trials (NCT03427814). BeiGene, a company based in Beijing, China, has developed pamiparib (BGB-290) and is currently progressing multiple phase II/III clinical trials. This substance, characterized as a fused pentacyclic dihydrodiazepinoindolone derivative, demonstrates significant efficacy against both PARP-1 and PARP-2 enzymes, with IC50 values of 1.3 and 0.9 nM, respectively. Furthermore, pamiparib exhibits substantial selectivity when compared to TNKS1 and TNKS-2, with IC50 values of 230 and 140 nM, respectively.722D skeletal formula with 2 carbonyls, CF3 group, F substituted benzene and multiple N atoms.Fluzopraib (SHR-3162) Jiangsu HengRui MedicineJiangsu HengRui Medicine Co., Ltd, China, is currently developing Fluzoparib. The compound is progressing in Phase II clinical trials (NCT05732129, not currently recruiting). Furthermore, a Phase 1 trial (NCT03509636) is in progress for patients with BRCA1/2-mutant OC. In a Phase I study, Fluzoparib, a PARP inhibitor, exhibited promising anti-tumor effects in advanced OC cases. This agent, also known as SHR3162 or HS10160, is an oral and highly potent PARP inhibitor that demonstrates anti-tumor properties, with a PARP1 IC50 of 1.46±0.72 nM.73,74A 2D skeletal formula of a fused bicyclic ring with C double bond O, N H, ethoxy and morpholine.Amelpraib (JPI-289) Jeil PharmaceuticalsThis molecule was developed by Jeil Pharmaceuticals, Korea. It is presently enduring Phase II clinical Trials (CT03062397). JPI-289, or Amelparib (free base), is a highly potent, orally available, and water-soluble PARP-1 inhibitor. This compound demonstrates nanomolar-range inhibition of PARP-1 (IC50=18.5 nM) and cellular PAR formation (IC50=10.6 nM). Amelparib shows promise as a neuroprotective agent and may have applications in acute ischemic stroke research. The substance exhibits promising potential as a neuroprotective agent in acute ischemic stroke; however, it has not demonstrated efficacy for acute kidney injury resulting from ischemia and has shown a negative impact on healing.75Tricyclic heteroaromatic with carbonyl, 3 ring nitrogens and fused indane side chain.Stenoparib (E7449, 2X-121, MGI25036)Allarity Therapeutics, a US-based company, is currently advancing this compound through Phase II clinical trials (NCT03562832). Stenoparib (E7449, 2X-121, MGI25036) is characterized as an orally administered, brain-penetrating small molecule that functions as a dual inhibitor of PARP1/2. This compound also demonstrates inhibitory effects on PARP5a/5b and possesses a unique dual-inhibitory mechanism targeting both PARP 1/2 and Tankyrase 1/2 (TNKS1/2), the latter being a crucial regulator of canonical Wnt/β-catenin signaling. The agent exhibits promising PARP inhibition (PARP1; C50=1.0 nM, and PARP2; IC50=1.2 nM). Additionally, the molecule shows efficacy in P-glycoprotein-expressing cells, indicating its potential to overcome certain forms of PARP inhibitor resistance.Line-angle skeletal formula of a fused bicyclic system with F, C double bond O and two NH groups.Rucaparib (Rubraca, AG014699, PF01367338)This molecule was developed by Pharmaand GmbH, Germany. At present, Phase III clinical trials are in evolution for rucaparib. In a cell-free assay, rucaparib phosphate demonstrates inhibition of PARP1 (Ki=1.4 nM) and exhibits binding affinity to a further 8 additional PARP domains (NCT04539327). It is the first PARP inhibitor utilized in clinical trials in combination with TMZ. This compound is under development for the therapy of OC associated with HR DNA repair deficiency (HRD) and is presently continuing in Phase 1/2 clinical trials (NCT01482715). Furthermore, investigators have assessed the safety as well as efficacy of rucaparib in individuals with relapsed OC harboring BRCA mutations.76Line-angle formula of fused rings linked to phenyl and cyclohexane, with H subscript 2 N C double bond O.Nirapraib (MK-4827) MerckThis molecule was developed by Merck. Niraparib, a PARP inhibitor, has received FDA consent to treat platinum-sensitive ovarian serous carcinoma. Phase III clinical trials have established its safety profile. This compound demonstrates selectivity for PARP inhibition (PARP1, IC50=3.8 nM and PARP2, IC50 = 2.1 nM) and demonstrates significant efficacy in cancer cells with BRCA1 and BRCA2 mutations. It exhibits greater than 330-fold selectivity against V-PARP, PARP3 and Tank1. Through the formation of PARP–DNA complexes, niraparib induces DNA damage, apoptosis, and cell death. At present, several clinical trials are investigating niraparib’s therapeutic potential for serous endometrial carcinoma (NCT05289648, Early Phase 1, Not yet recruiting). Monotherapy and a combination of niraparib and GSK4524101 for STs has also been evaluated (NCT06077877).Two dimensional skeletal structure with fused rings, two carbonyls, an O substituent and a piperazine.CEP-9722, proagent of CEP-8983, (Teva)CEP-9722, which functions as the proagent for CEP-8983, is a potent and orally administered inhibitor that specifically targets PARP-1 and PARP-2, with IC50 values of 20 nM and 6 nM, respectively. This compound exhibits anticancer properties and is at this time undergoing evaluation in Phase 1/2 Clinical trials (NCT01311713) under the supervision of Teva Branded Pharmaceutical Products R&D, Inc. The primary objective of these studies is to regulate the maximum tolerated dose that can be safely administered on a daily basis to patients with advanced or metastatic STs, as well as to measure the tolerability and safety of this established dose.A two-dimensional line-bond formula of a fused bicyclic ring linked to piperazine and an amide.AZD9574AZD9574 is a newly developed brain-penetrant compound with a distinct structural framework. It acts as a PARP inhibitor and demonstrates exceptional PARP1 selectivity (>8000-fold selectivity for PARP1 over PARP2), trapping ability, and enhanced CNS penetration within a single molecule. This compound exhibits PARP1 IC50 in the range between 0.3–2 nM. Experimental data from animal studies supports its advancement as a promising next-generation therapeutic candidate for addressing metastatic diseases and primary brain tumors. Thus, for patients with HRD+ BC that has metastasized to the brain, AZD9574 represents a potentially efficacious therapeutic intervention.77 A Summary of the Key PARPi Currently Undergoing Clinical Trials Core structure of first-generation PARP inhibitors. Structural characteristics of selected second-generation PARP inhibitors. Specificity is considered an essential element in reducing off-target effects and toxicities associated with PARPi.78 The 2nd-generation PARPi, such as NU1025 and PD128763, demonstrated more potency (>50-fold more potent) than 3-AB competitors. Numerous 3rd-generation PARPi with 3-AB are under development and have shown higher potency and superior specificity for PARP. The majority of 3rd-generation PARPi comprised benzamide-type or purine-type scaffolds (Figures 5 and 6). These included talazoparib (BMN 673; BioMarin/LEAD/Medivation), veliparib (ABT-888; AbbVie), niraparib (MK-4827; Tesaro/Merck), rucaparib (AG-014699; Clovis/Pfizer), and olaparib (AZD-2281; AstraZeneca/Kudos). These PARPi are available in the market at the commercial level or in late-phases (phases 2 and 3) clinical trials. However, some recently reported new PARPi have been used in pre-clinical or early stage clinical evaluations. Figure 5Chemical structures of selected third-generation PARP inhibitors.Six separate 2D skeletal chemical structures with text labels. Top left, Lynparza (Olaparib AZD-2281 slash KU-0059436): a left cyclopropyl group single bonded to a carbonyl C double bond O, then to a nitrogen linked to a six-membered saturated ring containing two nitrogens. That ring is single bonded to a carbonyl C double bond O attached to a benzene ring bearing one F substituent and a fused bicyclic system containing one carbonyl C double bond O and two adjacent N atoms, with one NH shown. Text: PARP1 IC50 equals 5 nM. PARP2 IC50 equals 1 nM. (Astrazeneca). Top middle, Rucaparib slash Rubraca (AG-014699 slash PF-01367338): a fused bicyclic system containing one carbonyl C double bond O and two NH labels, fused to a benzene ring bearing F, connected to a benzene ring, then to a two-carbon chain ending at an amine labeled NH with a methyl substituent. Text: IC50 equals 1 nM. (Clovis oncology slash Pharmaand GmbH). Top right, Niraparib, MK-4827, Tesaro (Zejula): a six-membered saturated ring containing one NH connected by a single bond to a benzene ring, then to an N atom linked into a fused bicyclic aromatic system containing two N atoms and bearing a carboxamide group C double bond O with NH2. Text: PARP1 IC50 equals 3.8 nM. PARP2 IC50 equals 2.1 nM. (Merck). Bottom left, Compound 7 Talazoparib (BMN 673) slash (Talzenna): a fused bicyclic system with one carbonyl C double bond O and multiple N atoms, fused to a benzene ring bearing F. This core is connected to a saturated ring junction showing wedge and dashed bonds and to a five-membered ring containing three N atoms, plus a benzene ring bearing F. Text: PARPi EC50 equals 5.48 nM. EIA IC50 equals 2.14 nM. PARP1 Ki equals 1.2 nM. PARP2 Ki equals 0.87 nM. (Lead Therapeutics slash BioMarin slash Medivation). Bottom middle, Veliparib (ABT888): a five-membered saturated ring containing NH connected through a chiral center marked with wedge and dashed bonds to an N-containing aromatic ring system bearing a carboxamide group C double bond O with NH2. Text: PARP1 Ki equals 5.2 nM. PARP2 Ki equals 2.9 nM. (Abbvie slash Abbott). Bottom right, CEP-9722, proagent of CEP-8983: a fused polycyclic system containing one lactam-like carbonyl C double bond O and an adjacent carbonyl C double bond O, one NH label on the fused ring system, an O substituent connected to a methyl group and a side chain to a six-membered saturated ring containing two nitrogens with one N-methyl substituent. Text: PARP1 IC50 equals 20 nM. PARP2 IC50 equals 6 nM. (Teva).Six 2D skeletal PARP inhibitor structures with PARP1 and PARP2 potency values. Figure 6Chemical structures of selected clinical-stage third-generation PARP inhibitors.Six chemical structures are described with their names and potencies. NO-1001 has an IC50 of 105 nM, featuring a morpholine-like ring linked to a polycyclic system with benzene rings. 2x-121, with an IC50 of 1 nM, includes a benzene ring fused to a five-membered ring and a bicyclic system with multiple N labels. CEP-8983 has an IC50 of 20 nM, showing a polycyclic system with NH and C=O groups and a benzene ring with O substituents. Pamiparib (BGB-290) has an IC50 of 0.83 nM, featuring a fused ring system with N labels and a benzene ring with an F substituent. Fluzoparib (SHR-3162) has an IC50 of 1.5 nM, with a bicyclic system linked to a benzene ring with an F substituent and a chain leading to a ring with N labels. Amelparib (JPI-289) has a PARP-1 IC50 of 18.5 nM and cellular PAR formation IC50 of 10.7 nM, featuring a bicyclic system with C=O and NH, a benzene ring with an O substituent and a chain leading to a tertiary N in a ring with O.Six 2D skeletal formulas of PARP inhibitors with IC subscript 50 values. Chemical structures of selected third-generation PARP inhibitors. Chemical structures of selected clinical-stage third-generation PARP inhibitors. Talazoparib, a highly effective PARP1/2 inhibitor approved for treating germline BRCA-mutated, HER2-negative advanced BC, is consistently highlighted in both preclinical and clinical studies for its remarkable ability to trap PARP. This mechanism involves the inhibitor stabilizing PARP-DNA complexes at DNA single-strand break sites, transforming them into deadly DSBs in cells deficient in homologous recombination. When compared to other clinically approved PARP inhibitors like olaparib, rucaparib, niraparib, and veliparib, talazoparib demonstrates significantly greater trapping potency. Quantitative studies indicate that its stabilization of PARP-DNA complexes can be approximately 100 times more potent than that of olaparib and rucaparib, and considerably higher than niraparib or veliparib, placing talazoparib at the forefront of PARP trapping efficiency within its class. This enhanced trapping is linked to its strong cytotoxic effects at nanomolar concentrations in BRCA-deficient models and supports its powerful anti-tumor activity at relatively low clinical doses (1 mg once daily), unlike the higher doses required for other PARP inhibitors. Mechanistically, this superior trapping is attributed to talazoparib’s unique structural characteristics that promote a strong PARP1/2-DNA interaction and extended retention on DNA, thereby increasing replication stress and synthetic lethality in HR-deficient tumors. These differences in PARP trapping potency are now widely acknowledged as a crucial differentiator in the pharmacodynamic profiles of PARP inhibitors and a vital factor in optimizing therapeutic strategies in oncology. Thus, talazoparib has emerged as one of the most promising PARP inhibitors in advanced-level clinical trials. It is significant to note that talazoparib was granted FDA approval for BC patients with inherited BRCA1/2 mutations in 2018 (US) and 2019 (Europe), following the promising outcomes of the EMBRACA randomized, phase III clinical trial;79 however, it has not yet been approved for OC treatment. The FDA granted approval in June 2023 for the use of talazoparib in combination with enzalutamide for the management of adult patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) mutations. Clinical trial data indicate that this combination therapy can reduce the risk of disease progression or death up to 55% in patients with HRR gene-mutated mCRPC. Furthermore, OC has long been recognized as the most lethal malignancy affecting the female reproductive system. It has been shown that over 15% of OC patients exhibit a defective BRCA-mediated HRR pathway, which can be targeted therapeutically using PARPi such as talazoparib. The expansion of talazoparib’s clinical approval beyond BC has been hampered by its extremely strong systemic side effects, which are comparable to those of chemotherapeutics. Recent clinical and regulatory advancements have underscored the increasing significance of talazoparib as a next-generation PARP inhibitor in precision oncology. Beyond its established role in germline BRCA-mutated BC, talazoparib has been incorporated into prostate cancer treatment following regulatory approvals endorsing its combination with the androgen-receptor signaling inhibitor enzalutamide for HRR gene–mutated metastatic castration-resistant prostate cancer (mCRPC).80 Evidence from the phase III TALAPRO-2 study demonstrated that the dual targeting of DNA-damage repair and androgen-receptor signaling provides clinically meaningful and durable benefits compared to androgen-receptor inhibition alone, ultimately leading to regulatory endorsement by the US FDA and subsequent clinical adoption.81,82 Nonetheless, the FDA has opted not to expand the labeling for the combination of talazoparib and enzalutamide to include patients with mCRPC who possess non–homologous recombination repair (HRR) gene mutations.83 Updated analyses reported through 2025–2026 further substantiate the robustness of this strategy, confirming sustained disease control and survival advantages, particularly in tumors harboring HRR alterations such as BRCA1/2. These developments highlight talazoparib’s potent PARP-trapping capability and its capacity to enhance synthetic lethality when paired with complementary targeted therapies. Ongoing clinical programs are investigating talazoparib across disease settings, additional STs, and combination regimens involving immunotherapies and other DNA-damage response inhibitors. Such efforts aim to overcome resistance mechanisms, refine biomarker-guided patient selection, and expand the therapeutic scope of PARP inhibition, positioning talazoparib as an increasingly integral component of future precision-oncology strategies. In the subsequent sections, we present and comprehensively summarize the most significant findings from discovery to phases 1, 2, and 3 of clinical trials assessing the efficacy of talazoparib as a PARPi for the treatment of STs, BC, and OC. The most recent data related to clinical trials of talazoparib in BC, OC, and STs are summarized in Clinical Trial Data of Talazoparib (Phase III). Discovery and Development Strategy of Talazoparib Talazoparib has been discovered and developed as a highly selective, novel, and effective PARP1/2 inhibitor. It was identified by lead optimization during the discovery and expansion of a novel series of tetrahydropyridophthlazinones as PARP 1/2 inhibitors. The IUPAC name of talazoparib (BMN 673) is (8S, 9R)-5-fluoro-8-(4-fluorophenyl)-9-(1methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,de] phthalazin-3-one).84 Talazoparib was first synthesized by Lead Therapeutics and was developed by BioMarin in 2010. which, in 2015 it was transferred to Medivation.85 A comprehensive study by Wang et al on various substituted tetrahydropyridophthlazinone derivatives identified talazoparib as the most efficacious anti-cancer agent. The discovery and development of talazoparib were first reported by Wang et al in 2016.84 During this discovery, after synthesizing several compounds bearing heteroaryl moieties at positions 8 and 9 of tetrahydropyridophthalazinone, a series of compounds bearing 9-azoles was exploited. The enzymatic PARP1 inhibition activity of all prepared analogs was compared with that of rucaparib (AG-014699), which was used as a standard in the evaluation.61 These compounds were then established in three supplementary functional assessments, in addition to the PARP1 inhibition assay, including a Capan-1 cytotoxicity assay to demonstrate the single-agent anti-tumor activity in BRCA2-mutation, a cellular PARylation assay to evaluate their proficiency in intracellular PARP1/2 inhibitory activity, and a Temozolomide (TMZ) sensitization assay to determine their cell-killing ability. In this series, Compound (1), having 9-(thiazol-2-yl) moiety, exhibited an enzymatic activity IC50 = 7.35 nM that was slightly decreased compared to the rucaparib (IC50 = 1.98 nM). Compound (2), bearing a 9-(1-methyl-pyrazol-5-yl) group, showed an inhibitory activity comparable to that of the PARP enzyme with rucaparib. The PARP1 inhibition potency of compound (2) with an IC50 of 1.84 nM and single-agent activity in Capan-1 cells (EC50 = 0.956 µM) was observed. Compound (3) demonstrated effective PARP1 inhibitory activity with an IC50 of 2.6 nM but the single-agent activity in the Capan-1 assay was much lower (EC50 = 172 µM). Compound (4) in which the (4-methyl-1,2,4-triazol-3-yl) group was present at position 9 showed EC50 = 0.17 µM, showed metabolic stability (rLM t1/2 = 6.9 h). Although there was an elusive structural difference between compounds (3) and (4), their single-agent activity differences were considerable (25-fold difference). Compound (5) was obtained by replacing the 5-fluoro in (3) with hydrogen, which showed the same enzymatic activity (IC50 = 2.7 nM) which was identical to analog (3). Likewise, the introduction of 4-fluorophenyl at position 8 into (3), led to the synthesis of compound (6). In the resulting analog (6), single-agent cytotoxicity was further diminished to a single-digit nanomolar range approximately 19-fold higher than (3) but exhibited enhanced cellular activities, such as chemosensitization (GI50 = 44 µM), PARylation (EC50 = 6.94 nM), and single-agent cytotoxicity (EC50 = 0.071 µM). Because of the excellent biological potential measured for (5) and (6), further synthetic extension was executed for the synthesis of a compound in which the tetra-hydropyridophthalazinone core was switched with 5-fluoro, 8-(4-fluorophenyl), and 9-(1methyl-1,2,4-triazol-5-yl) moieties. This substitution led to the development of (8S,9R) and talazoparib (BMN 673) (7) as shown in Scheme 1. Compound (7) was identified as the most potent compound in that series. Through SFC separation, enantiomers were successfully isolated, resulting in significant enhancements in both the separation efficiency and scalability. The active enantiomer of compound (7) had an absolute configuration which was determined by X-ray crystallography of its tosylate salt crystal. This analysis showed that the active enantiomer of (7) has an (8S,9R) configuration. Interestingly, another enantiomer of (7) was found to be inactive in the (8R,9S) configuration. The unique binding of the enantiomer possessing a trans-(8S,9R)-configuration involving fluoroaryl and 1,2,4-triazole groups establishes specific non-covalent π- and hydrogen-bonding interactions with key PARP1 amino acid residues. It has been demonstrated that such interactions are essential for inhibiting PARP-mediated PARylation, enhancing metabolic stability, and augmenting cytotoxic effects.86 Scheme 1The strategic development of talazoparib (7) from 4-nitroisobenzofuranone through different intermediates and compound (1) having 9-(thiazol-2-yl) moiety.The synthesis of talazoparib (Compound 7) from 4-nitroisobenzofuranone involves several chemical reactions. Starting with a lactone and carbocyclic ring containing nitro and fluorine groups, the process includes aldehyde coupling with triethylamine and acetic anhydride in 2-methyltetrahydrofuran, methanol ring-opening, titanium trichloride reduction and hydrazine cyclization. These steps produce intermediates with carbonyl, nitro, or amino groups and various aryl or heteroaryl substituents. The final product is a bicyclic tetrahydropyridophthalazinone with stereochemistry at positions 8 and 9. SFC chiral separation isolates the active trans (8S, 9R) enantiomer. A panel displays six analog structures with assay values: PARP inhibition EC50, PARP-1 IC50, Capan-1 EC50, TMZ GI50 and rat liver microsomal half-life. Talazoparib is the most potent, with a TMZ GI50 of 19 µM and PARP1 Ki of 1.2 nM. Numeric values for each compound are detailed in the figure.Talazoparib synthesis from 4-nitroisobenzofuranone with activity data for Compounds 1-7 in 2D scheme. The strategic development of talazoparib (7) from 4-nitroisobenzofuranone through different intermediates and compound (1) having 9-(thiazol-2-yl) moiety. Compound (7) possesses cellular PARylation (EC50 = 5.48 nM) and enzymatic inhibitory activity (IC50 = 2.14 nM). It also exhibited metabolic stability (rLM t1/2 = 359 min), but more prominently, it attained remarkable cytotoxicity either as a single agent in Capan-1 cells (EC50 = 0.008 µM) or in combination with other reagents, including TMZ, in a chemosensitization assay (GI50 = 19 µM). Talazoparib showed excellent efficacy in inhibiting the enzymatic activity of PARP1 (Ki = 1.2 nM) and PARP2 (Ki = 0.87 nM). It displayed remarkable anticancer potency in BRCA1-mutation MX-1 BC xenograft models, eg EC50 of talazoparib (7) in BRCA1-deficient MX-1 cells and BRCA2-deficient Capan-1 cells were >2000 times lower than those of veliparib and >50X less than the EC50 of olaparib.61,84 Talazoparib exhibited promising in vitro safety profiles and displayed exceptionally effective in vitro anticancer activity, especially in BRCA1/2-deficient cells (EC50 (Capan-1) = 5 nM; EC50 (MX1) = 0.3 nM), as well as excellent pharmacokinetic properties.87 The high potency of Talazoparib as a PARP inhibitor has been reported by Murai et al who described a mechanistic rationalization for the excellent anticancer activity of talazoparib (7) compared to other PARPi88 Talazoparib also exhibits good oral bioavailability and excellent liver microsome stability. These properties have enabled talazoparib (7) to show a significant anticancer effect at much lower doses in xenograft models following oral dosing, making it a favorable anticancer agent.61 Pommier et al reported that talazoparib exhibits significantly higher cytotoxicity as a single agent or in combination with other alkylating agents, and its potency in trapping PARP-DNA complexes is 100-fold greater than that of other PARPi. Talazoparib (7) can strongly trap PARP enzymes and possesses unique antitumor-killing activity.88,89 The superb potency and pharmacokinetic characteristics of talazoparib (7) after oral administration were translated into in vivo anti-tumor efficacy as a single agent in BRCA1 deficient MX-1 BC xenograft model and several other xenograft tumor models.61 A summary of in vitro activities of the five enantiomer pairs after chiral resolution is shown in Table 2. Table 2Comparison of the in vitro Potential and Metabolic Stability of 8, 9-Substituted Tetra-Hydropyridophthalazinone Compounds Obtained During the Development of TalazoparibCompCellular PARP Inhibition EC50 (nM)PARP-1 Enzyme IC50 (nM)Capan-1 (BRCA2- Deficient) EC50 (μM)TMZ Chemo- Sensitization GI50 (nM)rLM T1/2 (Min)Rucaparib4.691.980.61144Not given124.47.35106ND29.331.840.956>400ND3242.60.0092447241492.40.170>4004145>4002.764.3444ND66.942.290.07144>12075.482.140.00819359Notes: *F = Fluoro, Rucaparib= Standard drug.Abbreviation: ND, Not determined. Table 2Comparison of the in vitro Potential and Metabolic Stability of 8, 9-Substituted Tetra-Hydropyridophthalazinone Compounds Obtained During the Development of TalazoparibCompCellular PARP Inhibition EC50 (nM)PARP-1 Enzyme IC50 (nM)Capan-1 (BRCA2- Deficient) EC50 (μM)TMZ Chemo- Sensitization GI50 (nM)rLM T1/2 (Min)Rucaparib4.691.980.61144Not given124.47.35106ND29.331.840.956>400ND3242.60.0092447241492.40.170>4004145>4002.764.3444ND66.942.290.07144>12075.482.140.00819359Notes: *F = Fluoro, Rucaparib= Standard drug.Abbreviation: ND, Not determined. Comparison of the in vitro Potential and Metabolic Stability of 8, 9-Substituted Tetra-Hydropyridophthalazinone Compounds Obtained During the Development of Talazoparib Notes: *F = Fluoro, Rucaparib= Standard drug. Abbreviation: ND, Not determined. Gram Scale Synthesis of Talazoparib Guangzhou Well-Health Bio-Pharmaceutical Co., Ltd. reported the gram-scale synthesis of talazoparib in 99.5% (Scheme 2).90 This offers several benefits: it involves fewer reaction steps, is easy to implement, does not require metal catalysts or low temperatures, and is well suited for industrial-scale production (WO2017215166A1). Given the importance of PARPi and talazopriab, Li et al reported a light-activated talazoparib prodrug that exhibited good stability and was rapidly deprotected after UV irradiation.91 Scheme 2Gram scale synthesis of talazoparib.The synthesis of talazoparib involves four steps. Step one: methyl 3-amino-5-fluorobenzoate reacts with 4-fluorophenyl beta-keto acid in dioxane using pyridinium p-toluenesulfonate and magnesium sulfate, followed by sodium borohydride reduction, forming a dihydroquinolinone intermediate. Step two: chiral resolution of the intermediate with ethanol and D-tartaric acid under reflux yields the S-enantiomer. Step three: the intermediate reacts with chloro-methyl-triazole in tetrahydrofuran with sodium alcoholate, producing a triazole-substituted methyl ester with S stereochemistry. Step four: hydrazinolysis with hydrazine in ethanol converts the methyl ester to a hydrazide carbonyl group, resulting in talazoparib.Gram-scale talazoparib: cyclization, resolution, alkylation, hydrazinolysis from methyl 3-amino-5-fluorobenzoate. Gram scale synthesis of talazoparib. Clinical Therapeutics of Talazoparib Metastatic BC (mBC) is the main cause of cancer-related death in many populations. Although there has been much work in clinical development in recent years, therapies that mainly target mBC remain inadequate and fail to decrease the death rate in late-stage BC. A coherent combination of therapeutic agents targeting micro-environmental components and intrinsic tumor properties provides an encouraging strategy to improve these therapies with less toxicity and higher specificity. Until 2013, patients diagnosed with metastatic and/or locally advanced BC had a 5-year survival rate of approximately 26% at the time of analysis,92 revealing a need for both understanding of the metastatic process and the development of new therapies. This discrepancy in decreasing mortality between early- and late-stage mBC is a standard problem with BC administration. A total of 25 oncology drugs approved by the FDA can be categorized into three groups: cytotoxic chemotherapy, endocrine therapy, and targeted therapies for treating BC. The majority of these FDA-approved drugs are classified as cytotoxic chemotherapies (44%), targeted therapies (16%), and endocrine therapies (24%). Regarding HER-2 targeting therapies, only four drugs (16%) targeted microenvironment-specific molecules and intrinsic tumors. The limited availability of targeted therapies has been exacerbated by numerous significant issues in mBC treatment of mBC. Among these issues, the most important is the variation in response rates to systematic chemotherapy; results indicate that only 50% of metastatic cancers respond, in contrast to 90% of primary tumors. A lower RR in mBC is associated with an increased likelihood of acquired resistance to therapeutics.93,94 In 2013, combinatorial therapies were developed to target both the associated stromal components and drivers of metastasis. Targeted drug transport to tumor cells, illustrated by the antibody-drug conjugate (ADC) discovered by Sassoon et al and Sievers et al, has emerged as a new and encouraging approach for treating mBC.95,96 The management of ADC leads to high intra-carcinomal drug concentrations, even though the non-target tissues are mainly protected from chemotherapeutic disclosures.97 Clinical trials involving the use of platinum compounds, in addition to other drugs, in metastatic settings have demonstrated conflicting results. Platinum-based compounds have demonstrated efficacy in the treatment of metastatic diseases and have emerged as the primary therapeutic option for BRCA-positive individuals. A phase 1 trial of talazoparib (NCT01286987) showed the single-agent anti-tumor activity with an ORR of 33% in BRCA-mutated BC.92 Phase 2 was a 2-cohort trial with an optimal Simon strategy involving two stages that evaluated the activity of talazoparib in BRCA 1/2 BC (wild-type). In this study, participants were selected from one of two parallel cohorts. Patients with advanced TNBC with an underlying HRD assay were included in the first cohort (n=29), whereas the second cohort (n=29) included patients with advanced HER2-negative BC with a germline or somatic deleterious mutation in a non-BRCA 1/2 HR gene pathway. During this treatment, qualified patients received talazoparib orally (4 weeks, 1.0 mg/day) until disease progression (NCT02401347).98 An ongoing international phase III trial (EMBRACA) of talazoparib in BRCA-mutation with metastatic and/or locally advanced BC has been launched. Tables 3–5 summarize various clinical trials of talazoparib for BC, OC, and STs, respectively. Table 3An Overview of the Clinical Trials of Talazoparib for BC TreatmentPatients (Phase)DescriptionPopulationOutcomeTrial, StatusStudy RefN=28(I)Two-parts study: 1)-Dose escalation part (N=18) and, 2)-Expansion part (N=17). (1 mg/day; 0.75 mg/day oral administration, each cycle comprised of 28 days. A moderate renal impairment was observed.A total of 19 Japanese individuals having metastatic or locally advanced gBRCA1/2m BC were recruited and included in the study.99Stable disease was recorded in 36.8% of patients, while the ORR attained 57.9%. The OS rate at 12 months was 84.7%, and the PFS exhibited a median of 7.2 months (95%).Open-label study, Multicenter (Phase I) study (NCT03343054). It is active but not recruiting at this time.[99]N=84(II)Two phases, a 2-cohort study using 1mg of Talazoparib in gBRCAm carriers. Cohort A: PR or CR to a previous regimen that contained platinum Cohort B: Had more than two previous CTH regimens but no prior platinum treatment.1)-TNBC 59% (Cohort A) and 17% (Cohort B),2)-Locally advanced or mBC,3)-gBRCAm1)-ORR was 21% (Cohort A) and 37% in (Cohort B, 2)-CBR (CR, PR or SD for > 24 wks),3)-PFS: (Cohort A: 4 months, Cohort B: 5.6 months), 4)-OS: (Cohort A: 11.8 months, Cohort B: 16.5 months),5)- Safety and adverse events,6)-Pharmacodynamics7)- Standard of life,8)-All grades of adverse events (AE) include fatigue (45%), nausea (42%) and anemia (52%), were observed.NCT02034916 Primary analysis completed[100]N=20(II)Arm 1: 6 cycles of talazopraib followed by the doctor’s recommended course of care therapy, Arm 2: Four to six cycles of talazopraib tracked by surgery.Talazoparib (single agent) x one tablet for each day for 6 months. Insignificant toxicity found without chemotherapy yielded a substantial RCB-0 rate.1)- HER2-negative BC with tumour more than 1.0 cm,2)-Neoadjuvant setting,3)- gBRCAm BC (N=16 (gBRCA1, N=4 gBRCA2 positive)1)-Adverse events and safety,2)-Clinical outcomes in the neoadjuvant setting,3)-Predictive biomarkers(NCT03499353, and NCT02282345) This study is active and recruiting[101]N=29(II)1 mg daily of talazoparib was administered: Cohort A: TNBC with HRD determined based on Myriad HRD Assay. Cohort B: HER2-negative BC or solid tumor with a deleterious inherited or cancer-related somatic alteration in any of these genes: PTEN, ATR, MRE11, RAD51D, RAD51C, RAD50, BRIP1, BARD1, NBNM ATM, CHEK2, PALB2, or genes in the Fanconi anemia complementation1)-BRCA1/2 wild-type advanced TNBC and HRD, 2)-HER2-negative BC or other solid cancers with a mutation in a gene involved in the HR pathway1)-ORR,2)-CBR,3)-PFS,4)-AEs(NCT02401347)Recruiting[102]N=431(III)Out of 412 patients (N=286, talazoparib), took ≥1 dose of talazoparib, and (N = 126, physician’s opted chemotherapy.Among patients treated with talazoparib, 52.4% (150 individuals) experienced adverse events that necessitated a dose reduction.Superior efficacy, favourable PROs, and lower HRU rate, and grade 3–4 AEs were observed.EMBRACA Phase III study (NCT01945775), Completed[103]N=5000(II)I-SPY2 study, Standard therapy: Weekly doses of Paclitaxel 80 mg/m2, succeeded either Cyclophosphamide or Doxorubicin (standard of therapy).Experimental arm: Talazoparib plus Irinotecan and others terminated.Eligibility criteria include:1)-Operable BC in stages II–III with a maximum dimension of at least 2.5 cm,2)-Tumors of any ER/PgR and HER-2 status,3)-pre-surgical treatment contexts1)-Probability of enhanced pCR through the incorporation of experimental agents into standard neoadjuvant therapies2) Biomarkers for predicting and evaluating pCR3) PFS,4) OS,5) AEs,6) MRI volume measurement.NCT01042379Recruiting[104]N =10(II)A daily administration of 1 mg talazoparib in combination with 800 mg Avelumab was administered intravenously at biweekly intervals within a 28-day treatment cycle.The study involved two patient groups. The first group, Cohort 1: Included 10 individuals diagnosed with ccRCC exhibiting VHL alterations. These patients had all previously undergone ICB treatment. Cohort 2: comprised 8 patients with diverse renal cell carcinoma subtypes: four had FH-deficient RCC, one presented with SDH-deficient RCC, and three were diagnosed with RMC.Talazoparib inhibited the normal function of poly ADP-ribose polymerase enzymes, thereby impeding the self-repair and proliferation of cancer cells. PFS was 3.5 and 1.2 months in Cohorts 1 and 2, respectively. The most common AEs, such as anemia, nausea, and headache, were 28%, 22%, and 22% respectively.Single-center, investigator-initiated Phase II trial. A combined form of these agents was demonstrated to be safe; however, it was found to be ineffective in specific types of renal carcinoma.[105]N =61(II)Patients with TNBC who have an early-stage germline BRCA1/2 mutation were given talazoparib 1 mg once a day for 24 weeks.Among the 61 study participants, 48 completed at least 80% of their talazoparib treatment, underwent surgical procedures and were evaluated for pCR. The pCR rate was determined to be 45.8% in the treated group and 49.2% in the ITT population. Furthermore, the rate of RCB 0/I was determined to be 45.8% in the evaluable group and 50.8% in the ITT population.Although the predetermined pCR threshold was not attained but single-agent neoadjuvant talazoparib demonstrated efficacy. Most common TRAEs such as anemia, neutropenia, and headache were 39.3%, 9.8%, and 22%, respectively. No deaths occurred.Phase II, single-arm, open-label study (NCT03499353)Terminated[106]N=36(I/II)Biweekly doses of 800 mg of Avelumab were administered in combination with either Binimetinib (45 mg or 30 mg twice per day) or talazoparib (0.75 mg daily) plus Binimetinib (45 mg or 30 mg twice daily).1)-Avelumab in combination with Binimetinib 45 mg was administered to a group of 22 patients.2)-In the subset of DLT-evaluable individuals, 5 out of 11 individuals (45.5%) experienced DLT at the 45-mg dosage.3)-Additionally, a separate cohort of 13 patients received a combination of Talazoparib and Binimetinib 45 mg.107The combination of talazoparib or Avelumab with Binimetinib led to DLT rates that were higher than anticipated.Phase Ib/2, open-label, multicenter, safety, clinical activity, PK and PD study (Terminated)[107]N=431(III)The study participants were divided into two groups (Arms) with a 2:1 ratio. Arm 1, consisting of 287 individuals, received a daily dose of 1 mg talazoparib. Arm 2, comprising 127 participants, underwent standard therapy as determined by the physician, which included options such as Capecitabine, Eribulin, Gemcitabine, or Vinorelbine.Advanced BC with gBRCA1/2-mutated cohort,1)-inactive regionally developed, metastatic BC,2)- ≤ 3 previous CTH-inclusive regimens,3)-gBRCAm.1)-PFS (8.6 months),2)-ORR (62.6%),3)-OS,4)- AEs (anemia 55%),5)-pharmacodynamics,6)-Response interval,7)-Well-being of life. Talazoparib therapy showed significant benefits with good outcomes.Randomized, open-label, Phase II trial (NCT01945775)Active but not recruiting[79]N =21(II)A study was conducted to test talazoparib Beyond BRCA mutation. Previously pretreated advanced HER2-negative BC (n =13), and STs (n = 7) patients having other than gBRCA1/2 mutations were included.HER2-negative BC (n = 13), and STs (n = 7) patients with other than gBRCA1/2 mutations.The results indicate that the sensitivity of gPALB2 to PARP inhibition. The ORR (31%) and gPALB2-associated mutational signatures showed a link to tumor response.Open-label Phase II Trial Completed[108]N =33(III)EGFR2–negative gBRCA1/2-mutated advanced BC patients were randomized 2:1. The patients were enrolled from Asian regions (Korea and Taiwan).The patient received either chemotherapy (the doctor’s choice) or 1 mg of talazoparib daily.PFS (9 months for talazoparib-treated patients and 7.1 months for the physician’s choice chemotherapy. ORR (62.5% for talazoparib treated patients, 25.0% for the physician’s choice chemotherapy). OS (talazoparib: 20.7 months and for physician’s choice chemotherapy was 21.2 months). Grade 3/4 AEs.EMBRACA trial. Talazoparib was found to be optimal in Asian patients. Small groups of patients were the main limitation. (Active)[109]N=431(III)This study demonstrates the conclusive OS results obtained for talazoparib compared with chemotherapy. Patients were allocated 2:1 to either arm 1 or arm 2 Arm 1: 1mg of talazoparib on daily basis (N=287, talazoparib), OR Arm 2: Doctor’s discretion of chemotherapy (N=126, standard therapy).Advanced BC with gBRCA1/2-mutated cohort,1)-inactive regionally developed, metastatic BC,2)- ≤ 3 prior CTH-inclusive regimens,3)- gBRCAm.OS (talazoparib vs chemotherapy; 19.3 months vs 19.5 months). AEs were reported in 69.6% of patients receiving talazoparib and 64.3% of those undergoing chemotherapy. Mortality occurred in 75.3% of the talazoparib group and 75.0% of the chemotherapy group.Randomized Phase III trial (NCT01945775)Active but not recruiting[110]N=367 (II/III)This investigation examined the association between talazoparib exposure and the most prevalent severe (grade ≥ 3) hematopoietic AEs.1)-A total of N=286 patients were treated in the EMBRACA trial of talazoparib arm.2)-N=83 patients were from the Trial of ABRAZO.The study elaborates that modifying the dosing of talazoparib can effectively manage AEs.Phase II (ABRAZO) and Phase III (EMBRACA) Trials.[111]N=285 (III)This research examines the influence of talazoparib exposure, along with other baseline variables, on the PFR rate. 1mg of talazoparib on daily basis.: daily (as used in previous Trials).Advanced BC and gBRCA1/2 Mutated patients were recruited. A total of N=285 patients were treated with talazoparib.The suggested starting dose is 1 mg on a daily basis, which is the highest tolerable dose.Phase III EMBRACA Trials[112]N=84(II)This investigation examined the outcomes reported in patients with advanced BC who received talazoparib. The subjects had previously undergone Platinum-based treatment. Talazoparib was administered at a daily dosage of 1 mgPatients were administered talazoparib at a daily dosage of 1 mg. PROs were evaluated at baseline (first day) and subsequently at 6-week intervals during the initial 24-week period. Thereafter, assessments were conducted every 12 weeks until disease progression was observed.The research revealed notable improvements in breast and arm symptoms, along with an improved future perspective of patients observed in patients across both cohorts.ABRAZO was a Phase 2 study with two cohorts and two stages. (NCT02034916) (Terminated)[113]N=431(III)Study participants were allocated in a 2:1 ratio to one of two treatment groups. The first group (Arm 1) received a daily dose of 1 mg talazoparib, while the second group (Arm 2) was administered one of four medications selected by the physician: Capecitabine, Eribulin, Gemcitabine, or Vinorelbine.Out of 431 study participants, 287 were enrolled in the talazoparib group, while 144 received standard treatment. The inclusion criteria were:1) Metastatic or inoperable locally advanced BC,2) No more than 3 previous chemotherapy-containing regimens,3) Germline BRCA mutation.1)-PFS,2)-ORR was 62.6%,3)-hematologic AEs occurred in 55% of patients while non-hematologic AEs occurred in 32% of patients,4)- OS,5)- Pharmacodynamics,6)- Response interval,7)- Quality of life(NCT01945775)Active, not recruiting[79]N=84(II)Two-stages, two-cohort investigation of talazoparib 1 mg Group A: Partial or complete response to previous platinum-based treatment, Group B: More than 2 prior chemotherapy regimens, without previous platinum exposureThis trial enrolled participants with either(1) metastatic or locally advanced BC, or(2) germline BRCA mutation (gBRCAm).1)-Confirmed ORR was 23% (BRCA1), 33% (BRCA2), 26% (TN BC), and 29% (hormone receptor-positive),2)- CBR (CR, PR or SD for > 24 wk), ‎‎3)- PFS: (Cohort A: 4 mo, Cohort B: 5.6 mo),4)- OS: (Cohort A: 11.8 mo, Cohort B: 16.5 mo),5)-The most frequent AEs included anemia ‎‎(52%), fatigue (45%), and nausea (42%),6)- Pharmacodynamics7)- Quality of life(NCT02034916)Primary analysis completed[100]N=122(II)Arm 1: Six cycles of talazoparib treatment, followed by physician-selected standard care therapy. Arm 2: Four to six cycles of talazoparib treatment, followed by surgical intervention.1)-HER2-negative BC with a tumor larger than 1.0 cm;2)-Neoadjuvant environments; and3)-gBRCAm BC1)-AEs and safety,2)-Clinical response in the neoadjuvant setting,3)-Predictive biomarkers,4)-RCB-0 (pathologic complete response) rate was 53% and RCB-0/I was 63%,5)-Eight patients (40%) experienced grade 3 anemia.Non-randomized, open-label, multicenter study (NCT03499353) Active, recruiting[101]N=40(II)Daily administration of 1 mg talazoparib was allocated to two groups: Group A: TNBC patients exhibiting HRD, as determined by the Myriad HRD Assay. Group B: Patients with HER2-negative BC or other STs carrying a deleterious inherited or cancer-specific mutation in any of these genes: PTEN, ATR, MRE11, RAD51C, RAD51D, RAD50, BRIP1, BARD1, NBN, ATM, CHEK2, PALB2, or genes from the Fanconi anemia complementation group.1)-TNBC with wild-type BRCA1/2 and HRD,2)-Metastatic BC (HER2-negative) or other advanced STs with mutations in HER pathway genes.1)-ORR,2)- CBR,3)-PFS,4)-AEs(NCT02401347)Recruiting[114]N=1920(II)The standard treatment protocol was adopted: weekly administration of Paclitaxel at 80 mg/m2, followed by either Doxorubicin or Cyclophosphamide (the current standard of care). Alternative therapeutic approach: a combination of Irinotecan and Talazoparib1)- Operable BC in stages II–III with a maximum dimension of at least 2.5 cm2)- Tumors of any ER/PgR and HER-2 status3)- Preoperative treatment or n setting1)-Likelihood of enhanced pCR through the addition of experimental treatments to conventional neoadjuvant therapies,2)-Biomarkers that predict and indicate prognosis for pCR,3)- PFS,4)-OS,5)-AEs6)- MRI volumeI-SPY TRIAL (NCT01042379)Recruiting[115]Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program).Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. Table 4An Overview of Talazoparib Clinical Studies for OC TreatmentPatients (Phase)DescriptionPopulationOutcomeTrial, StatusRef StudyN=113(I)This trial was conducted in two phases: 1)-In the initial stage (part 1), 39 participants received talazoparib in varying doses, ranging from 0.025 to 1.1 mg daily, across nine different levels. 2)- Subsequently, an additional 71 subjects were administered talazoparib at a fixed dose of 1.0 mg per day in the second phase (part 2) of the study.Among the 113 cases of platinum-treated EOC, primary peritoneal cancer, or fallopian tube cancer, 34 were categorized as STs. Of these 34 EOC cases, 25 demonstrated gBRCAm.The ORR reached 41.7%. For patients with gBRCAm, the ORR was 55% in those sensitive to platinum, while it dropped to 20% in platinum-resistant cases. PFS extended to 36.4 months. Side effects related to treatment included fatigue, affecting 37% (26/71) of patients, and anemia, observed in 35% (25/71) of patients. Severe adverse events (grade 3 to 4) comprised anemia in 24% (17/71) of patients and thrombocytopenia in 18% (13/71) of patients.(NCT01286987)Completed[116]N=24(I)Daily administration of talazoparib at doses of 0.75 and 1 mg, in combination with weekly Carboplatin administration. A single treatment cycle comprised 21 days.1)-Among the enrolled patients, 2 out of 24 exhibited EOC with STs. 2)-Prior platinum CTH was administered to 58% (14/24) of the patients. 3)-The genetic analysis revealed gBRCAm in 29% (7/24) and sBRCAm in 12.5% (3/24) of cases.The study reported the following outcomes: 1)-Overall response rate was 14%, 2)-Disease control rate (DCR) reached 52%, 3)-Half of the patients required dose reductions, 4)- Three-quarters of participants (75%) experienced dose interruptions, 5)- Pharmacokinetic analysis was conducted.Completed[117]N=30(II)Enrolled participants in this study received a daily dose of 1 mg talazoparib.The study participants consisted of individuals with 1) epithelial OC, primary peritoneal cancer, or fallopian tube cancer, and 2) those in neoadjuvant settings.Initial concentration and impact of talazoparib on DNA copy number, loss of heterozygosity, and genetic mutations, as well as RNA and protein expression levels in HER deficiency-associated pathways prior to and following treatment.(NCT02316834)Ongoing[118]N/A(II)Arm 1: Enrolled participants in this study received a daily dose of 1 mg Talazoparib.Arm 2: TalazoparibThis study encompassed patients diagnosed with recurrent epithelial OC, as well as those with primary peritoneal or fallopian tube malignancies.ORR(NCT02836028)Withdrawn[119]N=3(II)Enrolled participants in this study received a daily dose of 1 mg talazoparib.1)-Recurrent and/or metastatic OC of epithelial origin,2)-Progression of disease during monotherapy with a PARP inhibitor,3) BRCA mutation in the germline.1)-OR (complete response + complete response),2) Safety,3) Response duration,4) Progression-free survivalPilot Study of BMN 673 (talazoparib)(NCT02326844) Ϯ[120]Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program).Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. Table 5A Summary of Clinical Trials of Talazoparib as a Single Agent in STsPatients(Phase)DescriptionPopulationOutcomeTrial, StatusStudyN=150(II)1 mg of talazoparib administered daily1)-Individuals with STs, 2)-Patients with somatic of gBRCAm, 3)- Study subjects with genomic mutations in other BRCA pathway genes (ATM, PALB2, Fanconi Anemia genes, ARIDIA, MER11, RAD50, NBS1, ATR)1)-CBR (CR, PR or SD > 24 w), 2)-PFS, 3)-OS, 4)-Baseline predictive molecular markers, 5)-Pharmacodynamics(NCT02286687)Recruiting[121]N=24(I/II)1 mg of talazoparib administered daily1)- Individuals were Pt-sensitive or nave EOC,2)- Patients showed recurrent primary peritoneal, BC, prostate, pancreas, gastric, or other STs and followed at least one conventional treatment, 3)- Somatic or gBRCAm1)-Pharmacodynamics, 2)-ORR(NCT01989546)Recruiting[122]No enrollmentDaily dose-escalation study for talazoparibThe study encompasses: 1) Individuals with advanced or metastatic STs (including CRPC, pancreatic cancer, mesothelioma, gastric cancer, NSCLC, SCLC, EOC, and TNBC), 2) Subjects presenting with varying degrees of hepatic and renal impairment1)-Patient safety and stability, 2)-Recommended Phase 2 Dose, 3)-Acceptability, 4)-Indicators of treatment efficacy and resistance, 5)-Objective Response Rate. 6)-Drug pharmacokinetics, 7)-Progression-Free Survival, 8)-Pharmacodynamic effects of the drug.(NCT02567396)Withdrawn[123]N=10(I)Arm 1: Daily oral administration of 1 mg talazoparib, Arm 2: Daily subcutaneous injection of 1 mg talazoparib was administered orally at a dose of 1 mg per day in cycles of 28 daysThe investigation encompasses advanced STs that have previously undergone 1–3 cycles of platinum-based chemotherapy.1)-Adverse events, 2)-Clinical benefit rate (complete response + partial response + stable disease for more than 24 weeks).(NCT03426254)Active, not Recruiting[124]N=9(I/II)The research employs oral administration of Talazoparib at a dosage of 1 mg daily, with treatment cycles lasting 28 days.1)-Patients with progressive STs who underwent 1–3 prior platinum-based chemotherapy regimens. 2)-Individuals diagnosed with advanced solid malignancies carrying confirmed or potential pathogenic mutations in BRCA1 or BRCA2 genes.1)-The overall response rate attained 55%. 2)-Primary pharmacodynamic (PD) endpoint, 67% of patients were evaluable. 3)-A statistically significant reduction in PARylation was observed in 83% of patients.(NCT01989546)Completed[125]N=15(I)Daily oral administration of 1 mg TalazoparibThe study investigated the pharmacological profile, tolerability, and anti-tumor activity of talazoparib as monotherapy in Chinese patients with advanced STs.1) TEAEs was 86.7%, 2) ORR was 6.7%, 3) 36.4% of patients had a stable illness, and 4) pharmacokineticsOpen-label (phase 1) study, completed(NCT04635631)[126]N=200(II)Administration of 800 mg of Avelumab‎ biweekly in conjunction with a daily dose of 1 mg Talazoparib.Two separate parallel cohorts were established for patients with advanced STs exhibiting BRCA1/2 or ATM alterations. The BRCA1/2 cohort demonstrated a response rate of 26.4% (42 patients), which included 9 complete responses (5.7%). In contrast, the ATM cohort showed a response rate of 4.9% (2 patients).The BRCA1/2 cohort exhibited an ORR of 26.4%, whereas the ATM cohort demonstrated an ORR of 4.9%, corresponding to two patients.A non-randomized, open-label, multicenter Phase 2b study with a tumor-agnostic approach, which was discontinued‎(NCT03565991)‎[127]N=223(I/II)Two-phase study: The investigation included Phase 1b with 12 participants and Phase 2 with 211 subjects. Both phases involved administering Avelumab and Talazoparib. In Phase 2, the dosage was set at 800 mg of Avelumab biweekly and 1 mg of Talazoparib daily.The study enrolled individuals with advanced STs. In total, 223 subjects, with an average (SD) age of 63 years, received treatment.ORR exhibited variation among patient cohorts, with 18.2% observed in those presenting with NBC and 34.8% in individuals diagnosed with hormone receptor-positive disease.Nonrandomized controlled trial, Terminated(NCT03330405)[128]Recruited Patients(Phase)DescriptionPopulationOutcomeTrial, StatusStudyN=43(I)The combination therapy comprises talazoparib administered in conjunction with Carboplatin AUC5-6 and Paclitaxel at a dosage of 80 mg/m2 on days 1, 8, and 15 within 21-day treatment cycles.The study included individuals with advanced STs. It is a dual-cohort investigation. Participants were recruited utilizing a 3 + 3 design and allocated into two cohorts. One cohort received Talazoparib for a week (plan A), while the other received it for three days (plan B).1)-Dose adjustments were observed in 87% and 100% of patients, respectively. 2)-TRAEs resulted in treatment discontinuation for 13% of patients in Schedule A and 10% in Schedule B. 3)-The primary toxicity observed was myelosuppression, which included grade 3/4 TRAEs.Completed(NCT02317874)[129]N=34(I)For a period of 22 days, patients received oral doses of talazoparib at 0.5 mg daily.This investigation enrolled subjects with advanced STs who exhibited either normal renal function or varying degrees of renal impairment.1)-This trial validates existing dosage guidelines for individuals with mild to moderate renal dysfunction. 2)-Additionally, the TEAE profile showed no significant variations across patient groups.Phase I, open-label, non-randomized study, completed (NCT02997163)[130]N=28(I)Talazoparib was administered orally once daily at a dose of 0.75 or 1 mg.This investigation enrolled Japanese participants with advanced local or metastatic STs, irrespective of mutations in DNA damage repair genes.‎TEAEs were anemia, stomatitis, maculopapular rash, decreased platelet count, decreased neutrophil count, and elevated alanine aminotransferase.‎Phase 1 trial, open-label, non-randomized, continuous, not recruiting (NCT03343054)[131]Patients(Phase)DescriptionPopulationOutcomeTrial, StatusStudyN=40(I/II)Talazoparib was administered orally at a dose of 400–600 µg/m2 (with a daily maximum of 800–1000 µg) on the first day, followed by oral TMZ at 20–55 mg/m2/day from days 2 through 6. The regimen was repeated every 28 days.The study enrolled participants ranging from 4 to 25 years of age, comprising both pediatric and adult subjects with STs that were either recurrent or refractory to treatment.In Phase 1: Prolonged SD was observed in 2 out of 5 EWS participants and 4 out of 25 non-EWS participants.In Phase 2: In the subsequent phase 2, none of the 10 EWS subjects experienced an OR, while two encountered prolonged SD.Completed(NCT02116777)[132]N=6(I)An oral solution of Talazoparib at a 1-mg dosage in combination with 14C-labeled Talazoparib at 100 µCiIndividuals who had an advanced solid tumor confirmed by histopathology and were at least eighteen years old were included in the study.Talazoparib demonstrated minimal metabolic activity. A primary route of elimination for unmetabolized Talazoparib was renal excretion.Phase 1 study, first in humans.Finalized (NCT01286987)[133]N=40(I)Administered Talazoparib at a daily dose ranging from 500 mcg to 1 mg prior to escalating the dosage of Temozolomide/IrinotecanPatients with advanced cancers who did not exhibit BRCA mutations were stratified into two cohorts for treatment. One group received a combination of Talazoparib and Temozolomide, while the other was administered Talazoparib in conjunction with Irinotecan.The combination of Talazoparib with low doses of Temozolomide or Irinotecan demonstrated acceptable tolerabilityPreclinical and clinical trials. Phase I dose-escalation study (accomplished)[134]N=47(II)The Talazoparib was administered at a dosage of 1 mg per day without interruption in 21-day cycles.1) FEP had tumors with deleterious mutation and had not previously been treated with a PARP inhibitor. 2) PAP represents a subgroup of FEP characterized by mutations in the ATM, ATR, BRCA1, BRCA2, or PALB2 gene.1)-PAP had an ORR of 4% and an OS of 95%; 2)-FEP had an ORR of 11%, which represented the DCR.Completed[135]N=33(I)Two Cohort Study: Patients in Cohort 1 (N = 25) and Cohort 2 (N = 8) were allocated daily doses of Talazoparib (0.1–2.0 mg).1)-The MTD was exceeded at 2.0 mg/day in cohort 1 and at 0.9 mg/day in cohort 2. 2)-Grade ≥3 adverse events were predominantly hematologic.1)-In patients with hematological malignancies, Talazoparib exhibited favorable tolerability, with an MTD comparable to that observed in STs.2)-Furthermore, the drug demonstrates preliminary evidence of efficacy against leukemia.Completed(NCT01399840)[136]N = 41(I)Cohorts of 3–6 subjects.-Talazoparib was administered orally, and Irinotecan was administered intravenously.2)-Talazoparib administered orally, Temozolomide administered orally, and Irinotecan administered intravenouslyBoth arms utilize a 3 + 3 designThe investigation encompassed pediatric patients with recurrent or refractory STs.1)-The research demonstrated that combining Talazoparib with Irinotecan and Temozolomide was found to be safe for use in pediatric patients.2)-The study identified the following adverse effects: 1) neutropenia, 2) thrombocytopenia, 3) febrile neutropenia, and 4) diarrheaStudy completed[137]N=24(I)Daily administration of talazoparib at doses of 0.75 and 1 mg, in combination with weekly carboplatin administration. A single treatment cycle comprised of 21 days.1)-Among the enrolled patients, 2 out of 24 exhibited EOC with STs. 2)-Prior platinum CTH was administered to 58% (14/24) of the patients. 3)-The genetic analysis revealed gBRCAm in 29% (7/24) and sBRCAm in 12.5% (3/24) of cases.The study reported the following outcomes: 1)-Overall response rate was 14%, 2)-DCR reached 52%, 3)-Half of the patients required dose reductions, 4)- Three-quarters of participants (75%) experienced dose interruptions, 5)- Pharmacokinetic analysis was conducted.Completed[117]N=223All patients were administered a combination of avelumab and talazoparib.1)-NSCLC patients, 2)- TNBC patients, 3)- mCRPC patients, 4)_BRCA1/2-altered OC patients, 5)- HR+ -BC patients,The combination of avelumab and talazoparib showed similar results to those observed with either PARPi or ICI monotherapy.Phase 1b and 2 basket nonrandomized controlled trial (NCT03330405).[128,138]N=28Patients had advanced STs, and 20 cancer types were enrolled and administered with talazopraib.Advanced solid tumorsTalazoparib showed effectiveness against tumors in individuals with advanced solid tumors and BRCA1/2 mutations.Phase II basket trial, NCT02693535, (completed in 2028)[139]N=341 mg/day and 0.75 mg/dayPatients with advanced STs who had normal kidney function or varying levels of kidney impairment.As renal impairment worsens, exposure to talazoparib increases, suggesting that patients with severe renal impairment should consider starting with a reduced dose of 0.5 mg/day.PHASE I OPEN-LABEL (NCT02997163, completed)[130]N=128Oral talazoparib (1 mg daily; or 0.75 mg daily for patients with moderate renal impairment) until the disease advancesMale patients with progressive, metastatic, castration-resistant prostate cancer of adenocarcinoma histology were enrolled.In men with advanced metastatic castration-resistant prostate cancer who had undergone extensive prior treatments, talazoparib demonstrated sustained antitumor effects, particularly in those with DDR-HRR gene mutations.Open-label, phase 2 trial (TALAPRO-1), NCT03148795, completed[140]N=36Talazoparib (1 mg once daily).Arm A [itraconazole], n = 19; Arm B [rifampicin], n = 17)Patients with advanced solid tumors were enrolled.The study focused on patients with advanced solid tumors to examine the effects of P-gp inhibition and induction on the pharmacokinetics of talazoparib.Open-label, 2-arm, drug-drug interaction Phase 1 study (NCT03077607).[141]Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program).Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. Table 3An Overview of the Clinical Trials of Talazoparib for BC TreatmentPatients (Phase)DescriptionPopulationOutcomeTrial, StatusStudy RefN=28(I)Two-parts study: 1)-Dose escalation part (N=18) and, 2)-Expansion part (N=17). (1 mg/day; 0.75 mg/day oral administration, each cycle comprised of 28 days. A moderate renal impairment was observed.A total of 19 Japanese individuals having metastatic or locally advanced gBRCA1/2m BC were recruited and included in the study.99Stable disease was recorded in 36.8% of patients, while the ORR attained 57.9%. The OS rate at 12 months was 84.7%, and the PFS exhibited a median of 7.2 months (95%).Open-label study, Multicenter (Phase I) study (NCT03343054). It is active but not recruiting at this time.[99]N=84(II)Two phases, a 2-cohort study using 1mg of Talazoparib in gBRCAm carriers. Cohort A: PR or CR to a previous regimen that contained platinum Cohort B: Had more than two previous CTH regimens but no prior platinum treatment.1)-TNBC 59% (Cohort A) and 17% (Cohort B),2)-Locally advanced or mBC,3)-gBRCAm1)-ORR was 21% (Cohort A) and 37% in (Cohort B, 2)-CBR (CR, PR or SD for > 24 wks),3)-PFS: (Cohort A: 4 months, Cohort B: 5.6 months), 4)-OS: (Cohort A: 11.8 months, Cohort B: 16.5 months),5)- Safety and adverse events,6)-Pharmacodynamics7)- Standard of life,8)-All grades of adverse events (AE) include fatigue (45%), nausea (42%) and anemia (52%), were observed.NCT02034916 Primary analysis completed[100]N=20(II)Arm 1: 6 cycles of talazopraib followed by the doctor’s recommended course of care therapy, Arm 2: Four to six cycles of talazopraib tracked by surgery.Talazoparib (single agent) x one tablet for each day for 6 months. Insignificant toxicity found without chemotherapy yielded a substantial RCB-0 rate.1)- HER2-negative BC with tumour more than 1.0 cm,2)-Neoadjuvant setting,3)- gBRCAm BC (N=16 (gBRCA1, N=4 gBRCA2 positive)1)-Adverse events and safety,2)-Clinical outcomes in the neoadjuvant setting,3)-Predictive biomarkers(NCT03499353, and NCT02282345) This study is active and recruiting[101]N=29(II)1 mg daily of talazoparib was administered: Cohort A: TNBC with HRD determined based on Myriad HRD Assay. Cohort B: HER2-negative BC or solid tumor with a deleterious inherited or cancer-related somatic alteration in any of these genes: PTEN, ATR, MRE11, RAD51D, RAD51C, RAD50, BRIP1, BARD1, NBNM ATM, CHEK2, PALB2, or genes in the Fanconi anemia complementation1)-BRCA1/2 wild-type advanced TNBC and HRD, 2)-HER2-negative BC or other solid cancers with a mutation in a gene involved in the HR pathway1)-ORR,2)-CBR,3)-PFS,4)-AEs(NCT02401347)Recruiting[102]N=431(III)Out of 412 patients (N=286, talazoparib), took ≥1 dose of talazoparib, and (N = 126, physician’s opted chemotherapy.Among patients treated with talazoparib, 52.4% (150 individuals) experienced adverse events that necessitated a dose reduction.Superior efficacy, favourable PROs, and lower HRU rate, and grade 3–4 AEs were observed.EMBRACA Phase III study (NCT01945775), Completed[103]N=5000(II)I-SPY2 study, Standard therapy: Weekly doses of Paclitaxel 80 mg/m2, succeeded either Cyclophosphamide or Doxorubicin (standard of therapy).Experimental arm: Talazoparib plus Irinotecan and others terminated.Eligibility criteria include:1)-Operable BC in stages II–III with a maximum dimension of at least 2.5 cm,2)-Tumors of any ER/PgR and HER-2 status,3)-pre-surgical treatment contexts1)-Probability of enhanced pCR through the incorporation of experimental agents into standard neoadjuvant therapies2) Biomarkers for predicting and evaluating pCR3) PFS,4) OS,5) AEs,6) MRI volume measurement.NCT01042379Recruiting[104]N =10(II)A daily administration of 1 mg talazoparib in combination with 800 mg Avelumab was administered intravenously at biweekly intervals within a 28-day treatment cycle.The study involved two patient groups. The first group, Cohort 1: Included 10 individuals diagnosed with ccRCC exhibiting VHL alterations. These patients had all previously undergone ICB treatment. Cohort 2: comprised 8 patients with diverse renal cell carcinoma subtypes: four had FH-deficient RCC, one presented with SDH-deficient RCC, and three were diagnosed with RMC.Talazoparib inhibited the normal function of poly ADP-ribose polymerase enzymes, thereby impeding the self-repair and proliferation of cancer cells. PFS was 3.5 and 1.2 months in Cohorts 1 and 2, respectively. The most common AEs, such as anemia, nausea, and headache, were 28%, 22%, and 22% respectively.Single-center, investigator-initiated Phase II trial. A combined form of these agents was demonstrated to be safe; however, it was found to be ineffective in specific types of renal carcinoma.[105]N =61(II)Patients with TNBC who have an early-stage germline BRCA1/2 mutation were given talazoparib 1 mg once a day for 24 weeks.Among the 61 study participants, 48 completed at least 80% of their talazoparib treatment, underwent surgical procedures and were evaluated for pCR. The pCR rate was determined to be 45.8% in the treated group and 49.2% in the ITT population. Furthermore, the rate of RCB 0/I was determined to be 45.8% in the evaluable group and 50.8% in the ITT population.Although the predetermined pCR threshold was not attained but single-agent neoadjuvant talazoparib demonstrated efficacy. Most common TRAEs such as anemia, neutropenia, and headache were 39.3%, 9.8%, and 22%, respectively. No deaths occurred.Phase II, single-arm, open-label study (NCT03499353)Terminated[106]N=36(I/II)Biweekly doses of 800 mg of Avelumab were administered in combination with either Binimetinib (45 mg or 30 mg twice per day) or talazoparib (0.75 mg daily) plus Binimetinib (45 mg or 30 mg twice daily).1)-Avelumab in combination with Binimetinib 45 mg was administered to a group of 22 patients.2)-In the subset of DLT-evaluable individuals, 5 out of 11 individuals (45.5%) experienced DLT at the 45-mg dosage.3)-Additionally, a separate cohort of 13 patients received a combination of Talazoparib and Binimetinib 45 mg.107The combination of talazoparib or Avelumab with Binimetinib led to DLT rates that were higher than anticipated.Phase Ib/2, open-label, multicenter, safety, clinical activity, PK and PD study (Terminated)[107]N=431(III)The study participants were divided into two groups (Arms) with a 2:1 ratio. Arm 1, consisting of 287 individuals, received a daily dose of 1 mg talazoparib. Arm 2, comprising 127 participants, underwent standard therapy as determined by the physician, which included options such as Capecitabine, Eribulin, Gemcitabine, or Vinorelbine.Advanced BC with gBRCA1/2-mutated cohort,1)-inactive regionally developed, metastatic BC,2)- ≤ 3 previous CTH-inclusive regimens,3)-gBRCAm.1)-PFS (8.6 months),2)-ORR (62.6%),3)-OS,4)- AEs (anemia 55%),5)-pharmacodynamics,6)-Response interval,7)-Well-being of life. Talazoparib therapy showed significant benefits with good outcomes.Randomized, open-label, Phase II trial (NCT01945775)Active but not recruiting[79]N =21(II)A study was conducted to test talazoparib Beyond BRCA mutation. Previously pretreated advanced HER2-negative BC (n =13), and STs (n = 7) patients having other than gBRCA1/2 mutations were included.HER2-negative BC (n = 13), and STs (n = 7) patients with other than gBRCA1/2 mutations.The results indicate that the sensitivity of gPALB2 to PARP inhibition. The ORR (31%) and gPALB2-associated mutational signatures showed a link to tumor response.Open-label Phase II Trial Completed[108]N =33(III)EGFR2–negative gBRCA1/2-mutated advanced BC patients were randomized 2:1. The patients were enrolled from Asian regions (Korea and Taiwan).The patient received either chemotherapy (the doctor’s choice) or 1 mg of talazoparib daily.PFS (9 months for talazoparib-treated patients and 7.1 months for the physician’s choice chemotherapy. ORR (62.5% for talazoparib treated patients, 25.0% for the physician’s choice chemotherapy). OS (talazoparib: 20.7 months and for physician’s choice chemotherapy was 21.2 months). Grade 3/4 AEs.EMBRACA trial. Talazoparib was found to be optimal in Asian patients. Small groups of patients were the main limitation. (Active)[109]N=431(III)This study demonstrates the conclusive OS results obtained for talazoparib compared with chemotherapy. Patients were allocated 2:1 to either arm 1 or arm 2 Arm 1: 1mg of talazoparib on daily basis (N=287, talazoparib), OR Arm 2: Doctor’s discretion of chemotherapy (N=126, standard therapy).Advanced BC with gBRCA1/2-mutated cohort,1)-inactive regionally developed, metastatic BC,2)- ≤ 3 prior CTH-inclusive regimens,3)- gBRCAm.OS (talazoparib vs chemotherapy; 19.3 months vs 19.5 months). AEs were reported in 69.6% of patients receiving talazoparib and 64.3% of those undergoing chemotherapy. Mortality occurred in 75.3% of the talazoparib group and 75.0% of the chemotherapy group.Randomized Phase III trial (NCT01945775)Active but not recruiting[110]N=367 (II/III)This investigation examined the association between talazoparib exposure and the most prevalent severe (grade ≥ 3) hematopoietic AEs.1)-A total of N=286 patients were treated in the EMBRACA trial of talazoparib arm.2)-N=83 patients were from the Trial of ABRAZO.The study elaborates that modifying the dosing of talazoparib can effectively manage AEs.Phase II (ABRAZO) and Phase III (EMBRACA) Trials.[111]N=285 (III)This research examines the influence of talazoparib exposure, along with other baseline variables, on the PFR rate. 1mg of talazoparib on daily basis.: daily (as used in previous Trials).Advanced BC and gBRCA1/2 Mutated patients were recruited. A total of N=285 patients were treated with talazoparib.The suggested starting dose is 1 mg on a daily basis, which is the highest tolerable dose.Phase III EMBRACA Trials[112]N=84(II)This investigation examined the outcomes reported in patients with advanced BC who received talazoparib. The subjects had previously undergone Platinum-based treatment. Talazoparib was administered at a daily dosage of 1 mgPatients were administered talazoparib at a daily dosage of 1 mg. PROs were evaluated at baseline (first day) and subsequently at 6-week intervals during the initial 24-week period. Thereafter, assessments were conducted every 12 weeks until disease progression was observed.The research revealed notable improvements in breast and arm symptoms, along with an improved future perspective of patients observed in patients across both cohorts.ABRAZO was a Phase 2 study with two cohorts and two stages. (NCT02034916) (Terminated)[113]N=431(III)Study participants were allocated in a 2:1 ratio to one of two treatment groups. The first group (Arm 1) received a daily dose of 1 mg talazoparib, while the second group (Arm 2) was administered one of four medications selected by the physician: Capecitabine, Eribulin, Gemcitabine, or Vinorelbine.Out of 431 study participants, 287 were enrolled in the talazoparib group, while 144 received standard treatment. The inclusion criteria were:1) Metastatic or inoperable locally advanced BC,2) No more than 3 previous chemotherapy-containing regimens,3) Germline BRCA mutation.1)-PFS,2)-ORR was 62.6%,3)-hematologic AEs occurred in 55% of patients while non-hematologic AEs occurred in 32% of patients,4)- OS,5)- Pharmacodynamics,6)- Response interval,7)- Quality of life(NCT01945775)Active, not recruiting[79]N=84(II)Two-stages, two-cohort investigation of talazoparib 1 mg Group A: Partial or complete response to previous platinum-based treatment, Group B: More than 2 prior chemotherapy regimens, without previous platinum exposureThis trial enrolled participants with either(1) metastatic or locally advanced BC, or(2) germline BRCA mutation (gBRCAm).1)-Confirmed ORR was 23% (BRCA1), 33% (BRCA2), 26% (TN BC), and 29% (hormone receptor-positive),2)- CBR (CR, PR or SD for > 24 wk), ‎‎3)- PFS: (Cohort A: 4 mo, Cohort B: 5.6 mo),4)- OS: (Cohort A: 11.8 mo, Cohort B: 16.5 mo),5)-The most frequent AEs included anemia ‎‎(52%), fatigue (45%), and nausea (42%),6)- Pharmacodynamics7)- Quality of life(NCT02034916)Primary analysis completed[100]N=122(II)Arm 1: Six cycles of talazoparib treatment, followed by physician-selected standard care therapy. Arm 2: Four to six cycles of talazoparib treatment, followed by surgical intervention.1)-HER2-negative BC with a tumor larger than 1.0 cm;2)-Neoadjuvant environments; and3)-gBRCAm BC1)-AEs and safety,2)-Clinical response in the neoadjuvant setting,3)-Predictive biomarkers,4)-RCB-0 (pathologic complete response) rate was 53% and RCB-0/I was 63%,5)-Eight patients (40%) experienced grade 3 anemia.Non-randomized, open-label, multicenter study (NCT03499353) Active, recruiting[101]N=40(II)Daily administration of 1 mg talazoparib was allocated to two groups: Group A: TNBC patients exhibiting HRD, as determined by the Myriad HRD Assay. Group B: Patients with HER2-negative BC or other STs carrying a deleterious inherited or cancer-specific mutation in any of these genes: PTEN, ATR, MRE11, RAD51C, RAD51D, RAD50, BRIP1, BARD1, NBN, ATM, CHEK2, PALB2, or genes from the Fanconi anemia complementation group.1)-TNBC with wild-type BRCA1/2 and HRD,2)-Metastatic BC (HER2-negative) or other advanced STs with mutations in HER pathway genes.1)-ORR,2)- CBR,3)-PFS,4)-AEs(NCT02401347)Recruiting[114]N=1920(II)The standard treatment protocol was adopted: weekly administration of Paclitaxel at 80 mg/m2, followed by either Doxorubicin or Cyclophosphamide (the current standard of care). Alternative therapeutic approach: a combination of Irinotecan and Talazoparib1)- Operable BC in stages II–III with a maximum dimension of at least 2.5 cm2)- Tumors of any ER/PgR and HER-2 status3)- Preoperative treatment or n setting1)-Likelihood of enhanced pCR through the addition of experimental treatments to conventional neoadjuvant therapies,2)-Biomarkers that predict and indicate prognosis for pCR,3)- PFS,4)-OS,5)-AEs6)- MRI volumeI-SPY TRIAL (NCT01042379)Recruiting[115]Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program).Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. An Overview of the Clinical Trials of Talazoparib for BC Treatment Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program). Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. Table 4An Overview of Talazoparib Clinical Studies for OC TreatmentPatients (Phase)DescriptionPopulationOutcomeTrial, StatusRef StudyN=113(I)This trial was conducted in two phases: 1)-In the initial stage (part 1), 39 participants received talazoparib in varying doses, ranging from 0.025 to 1.1 mg daily, across nine different levels. 2)- Subsequently, an additional 71 subjects were administered talazoparib at a fixed dose of 1.0 mg per day in the second phase (part 2) of the study.Among the 113 cases of platinum-treated EOC, primary peritoneal cancer, or fallopian tube cancer, 34 were categorized as STs. Of these 34 EOC cases, 25 demonstrated gBRCAm.The ORR reached 41.7%. For patients with gBRCAm, the ORR was 55% in those sensitive to platinum, while it dropped to 20% in platinum-resistant cases. PFS extended to 36.4 months. Side effects related to treatment included fatigue, affecting 37% (26/71) of patients, and anemia, observed in 35% (25/71) of patients. Severe adverse events (grade 3 to 4) comprised anemia in 24% (17/71) of patients and thrombocytopenia in 18% (13/71) of patients.(NCT01286987)Completed[116]N=24(I)Daily administration of talazoparib at doses of 0.75 and 1 mg, in combination with weekly Carboplatin administration. A single treatment cycle comprised 21 days.1)-Among the enrolled patients, 2 out of 24 exhibited EOC with STs. 2)-Prior platinum CTH was administered to 58% (14/24) of the patients. 3)-The genetic analysis revealed gBRCAm in 29% (7/24) and sBRCAm in 12.5% (3/24) of cases.The study reported the following outcomes: 1)-Overall response rate was 14%, 2)-Disease control rate (DCR) reached 52%, 3)-Half of the patients required dose reductions, 4)- Three-quarters of participants (75%) experienced dose interruptions, 5)- Pharmacokinetic analysis was conducted.Completed[117]N=30(II)Enrolled participants in this study received a daily dose of 1 mg talazoparib.The study participants consisted of individuals with 1) epithelial OC, primary peritoneal cancer, or fallopian tube cancer, and 2) those in neoadjuvant settings.Initial concentration and impact of talazoparib on DNA copy number, loss of heterozygosity, and genetic mutations, as well as RNA and protein expression levels in HER deficiency-associated pathways prior to and following treatment.(NCT02316834)Ongoing[118]N/A(II)Arm 1: Enrolled participants in this study received a daily dose of 1 mg Talazoparib.Arm 2: TalazoparibThis study encompassed patients diagnosed with recurrent epithelial OC, as well as those with primary peritoneal or fallopian tube malignancies.ORR(NCT02836028)Withdrawn[119]N=3(II)Enrolled participants in this study received a daily dose of 1 mg talazoparib.1)-Recurrent and/or metastatic OC of epithelial origin,2)-Progression of disease during monotherapy with a PARP inhibitor,3) BRCA mutation in the germline.1)-OR (complete response + complete response),2) Safety,3) Response duration,4) Progression-free survivalPilot Study of BMN 673 (talazoparib)(NCT02326844) Ϯ[120]Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program).Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. An Overview of Talazoparib Clinical Studies for OC Treatment Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program). Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. Table 5A Summary of Clinical Trials of Talazoparib as a Single Agent in STsPatients(Phase)DescriptionPopulationOutcomeTrial, StatusStudyN=150(II)1 mg of talazoparib administered daily1)-Individuals with STs, 2)-Patients with somatic of gBRCAm, 3)- Study subjects with genomic mutations in other BRCA pathway genes (ATM, PALB2, Fanconi Anemia genes, ARIDIA, MER11, RAD50, NBS1, ATR)1)-CBR (CR, PR or SD > 24 w), 2)-PFS, 3)-OS, 4)-Baseline predictive molecular markers, 5)-Pharmacodynamics(NCT02286687)Recruiting[121]N=24(I/II)1 mg of talazoparib administered daily1)- Individuals were Pt-sensitive or nave EOC,2)- Patients showed recurrent primary peritoneal, BC, prostate, pancreas, gastric, or other STs and followed at least one conventional treatment, 3)- Somatic or gBRCAm1)-Pharmacodynamics, 2)-ORR(NCT01989546)Recruiting[122]No enrollmentDaily dose-escalation study for talazoparibThe study encompasses: 1) Individuals with advanced or metastatic STs (including CRPC, pancreatic cancer, mesothelioma, gastric cancer, NSCLC, SCLC, EOC, and TNBC), 2) Subjects presenting with varying degrees of hepatic and renal impairment1)-Patient safety and stability, 2)-Recommended Phase 2 Dose, 3)-Acceptability, 4)-Indicators of treatment efficacy and resistance, 5)-Objective Response Rate. 6)-Drug pharmacokinetics, 7)-Progression-Free Survival, 8)-Pharmacodynamic effects of the drug.(NCT02567396)Withdrawn[123]N=10(I)Arm 1: Daily oral administration of 1 mg talazoparib, Arm 2: Daily subcutaneous injection of 1 mg talazoparib was administered orally at a dose of 1 mg per day in cycles of 28 daysThe investigation encompasses advanced STs that have previously undergone 1–3 cycles of platinum-based chemotherapy.1)-Adverse events, 2)-Clinical benefit rate (complete response + partial response + stable disease for more than 24 weeks).(NCT03426254)Active, not Recruiting[124]N=9(I/II)The research employs oral administration of Talazoparib at a dosage of 1 mg daily, with treatment cycles lasting 28 days.1)-Patients with progressive STs who underwent 1–3 prior platinum-based chemotherapy regimens. 2)-Individuals diagnosed with advanced solid malignancies carrying confirmed or potential pathogenic mutations in BRCA1 or BRCA2 genes.1)-The overall response rate attained 55%. 2)-Primary pharmacodynamic (PD) endpoint, 67% of patients were evaluable. 3)-A statistically significant reduction in PARylation was observed in 83% of patients.(NCT01989546)Completed[125]N=15(I)Daily oral administration of 1 mg TalazoparibThe study investigated the pharmacological profile, tolerability, and anti-tumor activity of talazoparib as monotherapy in Chinese patients with advanced STs.1) TEAEs was 86.7%, 2) ORR was 6.7%, 3) 36.4% of patients had a stable illness, and 4) pharmacokineticsOpen-label (phase 1) study, completed(NCT04635631)[126]N=200(II)Administration of 800 mg of Avelumab‎ biweekly in conjunction with a daily dose of 1 mg Talazoparib.Two separate parallel cohorts were established for patients with advanced STs exhibiting BRCA1/2 or ATM alterations. The BRCA1/2 cohort demonstrated a response rate of 26.4% (42 patients), which included 9 complete responses (5.7%). In contrast, the ATM cohort showed a response rate of 4.9% (2 patients).The BRCA1/2 cohort exhibited an ORR of 26.4%, whereas the ATM cohort demonstrated an ORR of 4.9%, corresponding to two patients.A non-randomized, open-label, multicenter Phase 2b study with a tumor-agnostic approach, which was discontinued‎(NCT03565991)‎[127]N=223(I/II)Two-phase study: The investigation included Phase 1b with 12 participants and Phase 2 with 211 subjects. Both phases involved administering Avelumab and Talazoparib. In Phase 2, the dosage was set at 800 mg of Avelumab biweekly and 1 mg of Talazoparib daily.The study enrolled individuals with advanced STs. In total, 223 subjects, with an average (SD) age of 63 years, received treatment.ORR exhibited variation among patient cohorts, with 18.2% observed in those presenting with NBC and 34.8% in individuals diagnosed with hormone receptor-positive disease.Nonrandomized controlled trial, Terminated(NCT03330405)[128]Recruited Patients(Phase)DescriptionPopulationOutcomeTrial, StatusStudyN=43(I)The combination therapy comprises talazoparib administered in conjunction with Carboplatin AUC5-6 and Paclitaxel at a dosage of 80 mg/m2 on days 1, 8, and 15 within 21-day treatment cycles.The study included individuals with advanced STs. It is a dual-cohort investigation. Participants were recruited utilizing a 3 + 3 design and allocated into two cohorts. One cohort received Talazoparib for a week (plan A), while the other received it for three days (plan B).1)-Dose adjustments were observed in 87% and 100% of patients, respectively. 2)-TRAEs resulted in treatment discontinuation for 13% of patients in Schedule A and 10% in Schedule B. 3)-The primary toxicity observed was myelosuppression, which included grade 3/4 TRAEs.Completed(NCT02317874)[129]N=34(I)For a period of 22 days, patients received oral doses of talazoparib at 0.5 mg daily.This investigation enrolled subjects with advanced STs who exhibited either normal renal function or varying degrees of renal impairment.1)-This trial validates existing dosage guidelines for individuals with mild to moderate renal dysfunction. 2)-Additionally, the TEAE profile showed no significant variations across patient groups.Phase I, open-label, non-randomized study, completed (NCT02997163)[130]N=28(I)Talazoparib was administered orally once daily at a dose of 0.75 or 1 mg.This investigation enrolled Japanese participants with advanced local or metastatic STs, irrespective of mutations in DNA damage repair genes.‎TEAEs were anemia, stomatitis, maculopapular rash, decreased platelet count, decreased neutrophil count, and elevated alanine aminotransferase.‎Phase 1 trial, open-label, non-randomized, continuous, not recruiting (NCT03343054)[131]Patients(Phase)DescriptionPopulationOutcomeTrial, StatusStudyN=40(I/II)Talazoparib was administered orally at a dose of 400–600 µg/m2 (with a daily maximum of 800–1000 µg) on the first day, followed by oral TMZ at 20–55 mg/m2/day from days 2 through 6. The regimen was repeated every 28 days.The study enrolled participants ranging from 4 to 25 years of age, comprising both pediatric and adult subjects with STs that were either recurrent or refractory to treatment.In Phase 1: Prolonged SD was observed in 2 out of 5 EWS participants and 4 out of 25 non-EWS participants.In Phase 2: In the subsequent phase 2, none of the 10 EWS subjects experienced an OR, while two encountered prolonged SD.Completed(NCT02116777)[132]N=6(I)An oral solution of Talazoparib at a 1-mg dosage in combination with 14C-labeled Talazoparib at 100 µCiIndividuals who had an advanced solid tumor confirmed by histopathology and were at least eighteen years old were included in the study.Talazoparib demonstrated minimal metabolic activity. A primary route of elimination for unmetabolized Talazoparib was renal excretion.Phase 1 study, first in humans.Finalized (NCT01286987)[133]N=40(I)Administered Talazoparib at a daily dose ranging from 500 mcg to 1 mg prior to escalating the dosage of Temozolomide/IrinotecanPatients with advanced cancers who did not exhibit BRCA mutations were stratified into two cohorts for treatment. One group received a combination of Talazoparib and Temozolomide, while the other was administered Talazoparib in conjunction with Irinotecan.The combination of Talazoparib with low doses of Temozolomide or Irinotecan demonstrated acceptable tolerabilityPreclinical and clinical trials. Phase I dose-escalation study (accomplished)[134]N=47(II)The Talazoparib was administered at a dosage of 1 mg per day without interruption in 21-day cycles.1) FEP had tumors with deleterious mutation and had not previously been treated with a PARP inhibitor. 2) PAP represents a subgroup of FEP characterized by mutations in the ATM, ATR, BRCA1, BRCA2, or PALB2 gene.1)-PAP had an ORR of 4% and an OS of 95%; 2)-FEP had an ORR of 11%, which represented the DCR.Completed[135]N=33(I)Two Cohort Study: Patients in Cohort 1 (N = 25) and Cohort 2 (N = 8) were allocated daily doses of Talazoparib (0.1–2.0 mg).1)-The MTD was exceeded at 2.0 mg/day in cohort 1 and at 0.9 mg/day in cohort 2. 2)-Grade ≥3 adverse events were predominantly hematologic.1)-In patients with hematological malignancies, Talazoparib exhibited favorable tolerability, with an MTD comparable to that observed in STs.2)-Furthermore, the drug demonstrates preliminary evidence of efficacy against leukemia.Completed(NCT01399840)[136]N = 41(I)Cohorts of 3–6 subjects.-Talazoparib was administered orally, and Irinotecan was administered intravenously.2)-Talazoparib administered orally, Temozolomide administered orally, and Irinotecan administered intravenouslyBoth arms utilize a 3 + 3 designThe investigation encompassed pediatric patients with recurrent or refractory STs.1)-The research demonstrated that combining Talazoparib with Irinotecan and Temozolomide was found to be safe for use in pediatric patients.2)-The study identified the following adverse effects: 1) neutropenia, 2) thrombocytopenia, 3) febrile neutropenia, and 4) diarrheaStudy completed[137]N=24(I)Daily administration of talazoparib at doses of 0.75 and 1 mg, in combination with weekly carboplatin administration. A single treatment cycle comprised of 21 days.1)-Among the enrolled patients, 2 out of 24 exhibited EOC with STs. 2)-Prior platinum CTH was administered to 58% (14/24) of the patients. 3)-The genetic analysis revealed gBRCAm in 29% (7/24) and sBRCAm in 12.5% (3/24) of cases.The study reported the following outcomes: 1)-Overall response rate was 14%, 2)-DCR reached 52%, 3)-Half of the patients required dose reductions, 4)- Three-quarters of participants (75%) experienced dose interruptions, 5)- Pharmacokinetic analysis was conducted.Completed[117]N=223All patients were administered a combination of avelumab and talazoparib.1)-NSCLC patients, 2)- TNBC patients, 3)- mCRPC patients, 4)_BRCA1/2-altered OC patients, 5)- HR+ -BC patients,The combination of avelumab and talazoparib showed similar results to those observed with either PARPi or ICI monotherapy.Phase 1b and 2 basket nonrandomized controlled trial (NCT03330405).[128,138]N=28Patients had advanced STs, and 20 cancer types were enrolled and administered with talazopraib.Advanced solid tumorsTalazoparib showed effectiveness against tumors in individuals with advanced solid tumors and BRCA1/2 mutations.Phase II basket trial, NCT02693535, (completed in 2028)[139]N=341 mg/day and 0.75 mg/dayPatients with advanced STs who had normal kidney function or varying levels of kidney impairment.As renal impairment worsens, exposure to talazoparib increases, suggesting that patients with severe renal impairment should consider starting with a reduced dose of 0.5 mg/day.PHASE I OPEN-LABEL (NCT02997163, completed)[130]N=128Oral talazoparib (1 mg daily; or 0.75 mg daily for patients with moderate renal impairment) until the disease advancesMale patients with progressive, metastatic, castration-resistant prostate cancer of adenocarcinoma histology were enrolled.In men with advanced metastatic castration-resistant prostate cancer who had undergone extensive prior treatments, talazoparib demonstrated sustained antitumor effects, particularly in those with DDR-HRR gene mutations.Open-label, phase 2 trial (TALAPRO-1), NCT03148795, completed[140]N=36Talazoparib (1 mg once daily).Arm A [itraconazole], n = 19; Arm B [rifampicin], n = 17)Patients with advanced solid tumors were enrolled.The study focused on patients with advanced solid tumors to examine the effects of P-gp inhibition and induction on the pharmacokinetics of talazoparib.Open-label, 2-arm, drug-drug interaction Phase 1 study (NCT03077607).[141]Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program).Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. A Summary of Clinical Trials of Talazoparib as a Single Agent in STs Note: Ϯ Terminated (closed by the Cancer Therapy Evaluation Program). Abbreviations: RCB, Residual cancer burden; CR, Complete response; BRCA, Breast cancer genes; VHL, Von Hippel-Lindau; CTH, Chemotherapy; ccRCC, Clear cell renal cell carcinoma; FH, Fumarate hydratase; RCC, Renal cell carcinoma; SDH, Succinate dehydrogenase; RMC, Renal medullary carcinoma; TNBC, Triple-negative breast cancer; TRAEs, Treatment-related adverse events; PK, Pharmacokinetic; PD, Pharmacodynamics; DLT, Dose-limiting toxicity; EGFR2, Epidermal growth factor receptor 2; gBRCA1/2m, Germline BRCA1/2 mutation; PFS, Progression-free survival; OS, Overall survival; PROs, Patient-reported outcomes; PARPi, Poly(ADP-ribose) polymerase inhibition; HRD, Homologous recombination deficiency; EOC, Epithelial ovarian cancer; LOH, Loss of heterozygosis; PARP, Poly(ADP-ribose) polymerase; ORR, Objective response rate; SD, Stable disease; PR, Partial response; pCR, Pathological complete response; IRB, immune checkpoint blockade; ITT, intent-to-treat; RCB, Rate of residual cancer burden; AEs, Adverse events; ATM, Ataxia-telangiectasia mutated gene; BC, Breast cancer; CRPC, Castration-resistant prostate cancer; BC, Breast cancer; CBR, Clinical benefit rate; ER/PgR, Estrogen and progesterone receptor; EOC, Epithelial ovarian cancer; HER2, Human epidermal growth factor receptor 2; HR, Homologous recombination; HRD, Homologous recombination deficiency; LOH, Loss of heterozygosis; MRI, Magnetic resonance imaging; EWS, Ewing sarcoma; FEP, Full eligible population; NSCLC, Non-small-cell lung cancer; OS, Overall survival; PAP, Primary analysis population; PFS, Progression-free survival; PO, Per OS (oral); SC, Subcutaneous; RP2D, Recommended phase II dose; SCLC, Small cell lung cancer; TEAEs, Treatment-emergent adverse events; TMZ, Temozolomide; wk, Weeks; MTD, Maximum tolerated dose; mo, Months; PR, Partial response; Pt, Platinum; QoL, Quality of life; ICI, Immune checkpoint inhibitor. Clinical Trial Data of Talazoparib (Phase I) Talazoparib (also identified as MDV 3800 and BMN 673) is an orally bioavailable PARP1/2 inhibitor that exhibits a dual mechanism.61,87,89,142 It has remarkable anticancer activity in BRCA-mutated patients with BC and OC.143 Talazoparib has both PARP-trapping activity and catalytic PARP-inhibition; however, its PARP-trapping effect is 100-fold higher than that of earlier generation PARP inhibitors.144 The initial clinical results reported in 2013 and updated in 2017 by De Bono et al demonstrated that talazoparib is a single-agent PARPi,145 revealing that its potency is much more to trap PARP-DNA complexes than that of earlier PARPi.87 Phase I dose escalation experiments determined the maximum tolerated dose (MTD) of talazoparib to be 1000 mg once per day. Talazoparib shows promising clinical activity. During the Phase 1 trial, 17 patients were recruited, 11 of whom had germaline BRCA (gBRCA)-associated primary peritoneal cancer (PPC) or OC and had a neutral response to talazoparib.146 In this dose-escalation trial, patients with OC were treated with talazoparib and TMZ. This study established the maximum tolerated dose (MTD) utilizing the standard dose of PARPi, in addition to a reduced dose of the sensitizing chemotherapeutic agent.144 A synergistic effect was detected when talazoparib was combined with TMZ or platinum drugs in a xenograft model. The PARPi dose was kept greater from the start at a prescribed amount with verified single-agent activity, whereas the TMZ dose was started at a lower dose and increased carefully until the MTD level was achieved. When assessed in chicken DT40 cell lines, PALB2 mutation predicted a unique in vivo response to talazoparib.145 Further experiments proved that the nanomolar cytotoxicity of talazoparib was higher than that of the early generation, which was assumed to be associated with the trapping of PARP-DNA complexes in knockout mouse models.88 The favorable preclinical results of talazoparib have enabled further investigation in several clinical trials, either alone or in combination with other agents, as reported in many clinical trials, including NCT02317874, NCT02116777, NCT02049593, and NCT02358200. It has completed a phase I clinical trial and is currently recruiting patients in phase II (ABRAZO) and III (EMBRACA) clinical trials to treat locally advanced and mBC with gBRCA1/2 deleterious mutations. ABRAZO is a phase 2 study of BC patients initially treated with gBRCA mutations147 while EMBRACA (NCT01945775) is an ongoing phase III trial (completed and not recruiting) assessing the effectiveness and safety of talazoparib in metastatic or locally advanced BC patients with BRCA mutations.148 Clinical Trial Data of Talazoparib (Phase II) The 2017 ASCO Annual Meeting (2017) by Nicholas et al of the Royal Marsden Hospital (RMH) and Institute of Cancer Research (ICR) in London revealed that talazoparib as a single agent has promising efficacy in patients with metastatic BC with gBRCA1/2 mutations in a phase II trial.149 ABRAZO (NCT02034916) was a phase II, 2-stage, 2-cohort, study of talazoparib at an optimal dose of 1 mg/day. Cohort 1 was platinum-based therapy, whereas Cohort 2 was based on ≥ 3 platinum-free cytotoxic-based treatments in patients with mBC and/or locally advanced BC, and gBRCA1/2 mutations. This study is not enlisting patients, but is an ongoing trial. The data for this phase 2 clinical trial (NCT02034916) were first posted in January 2014 and then updated in November 2017. The main objective of this phase 2 trial was to demonstrate the potency and safety profile of a single agent, talazoparib (BMN 673), in patients with metastatic or locally advanced BC with a deleterious gBRCA1/2 mutation.150 The patients had an ECOG PS ≤ 1 and assessable disease according to the RECIST v1.1. In this study, almost five responses for each cohort were required in ≤ 35 patients for the development of stage 2 in ≤ 35 patients.149 There were two endpoints in the ABRAZO trial for talazoparib. The primary endpoint was the objective response rate (ORR), while the secondary endpoints included the duration of response (DOR) and clinical benefit rate for ≥ 24 weeks (CBR24), overall survival (OS), and progression-free survival (PFS). The detail of the investigation studied, as provided by Pfizer, revealed that in primary and secondary endpoints (CBR 24 and DOR), the complete response (CR) for the disappearance of all non-target lesions and non-nodal targets, with non-target and target lymph node deterioration of less than 10 mm in the short axis. Partial response (PR) was found to as ≥30% decline in the sum of diameters of target lesions compared to the sum at baseline. An independent radiology facility (IRF) conducted response evaluation.150 The results showed that from May 2014 to Feb 2016, 84 patients were registered in a 2-cohort (C1, N = 49; C2, N = 35) 2-stage study, and nine patients continued treatment until September 1, 2016 (the data cutoff time). Both cohorts progressed to stage 2 before enrollment. The patients had a median age of 50 (range, 31–75) years; 41%/59% of patients had an HR+/TNBC incidence in C1 and 83%/17% in C2, while 58% of the patients had an ECOG PS of 0. The ORR by IRF for BRCA1/2 was 24%/34% and 29%/26% for HR+/TNBC, respectively. The most common AEs were observed in patients (20%) with neutropenia (27%), thrombocytopenia (33%), diarrhea (33%), nausea (42%), fatigue (45%), and anemia (52%). AEs (grade ≥ 3) revealed that participants only had neutropenia (15%), thrombocytopenia (19%), and anemia (35%), whereas the non-hematological adverse events (grade ≥ 3) did not come about. Adverse events (AEs) related to talazoparib had led to the discontinuation of drug in 4% of patients, ie only 3 patients, while 4 patients died from AEs unrelated to talazoparib. From phase II trial data, it was concluded that talazoparib was well tolerated in mBC patients with a gBRCA1/2 mutation, demonstrating favorable anticancer activity in cohorts 1 and 2.150 The phase II trial data for talazoparib, along with the recommended clinical response rate (RECIST) by tumor type, and the suggested dose level for phase 2 (1.0 mg/day) in patients treated with talazoparib have been reported. After the Phase 2 study, a Phase 3 EMBRACA trial (NCT01945775) of talazoparib vs. the physician’s choice of treatment in gBRCA1/2-mutated metastatic BC was assessed, as discussed in the following section. Clinical Trial Data of Talazoparib (Phase III) Talazoparib was generally well tolerated and has shown encouraging single-agent anti-cancer efficacy in several solid tumor types in Phase I/II clinical trials.151 This international Phase III trial, EMBRACA (NCT01945775), compares the safety and efficacy of talazoparib versus the physician’s choice in patients with advanced BC. Data related to the EMBRACA trial of talazoparib were first posted in September 2013 and updated in September 2017.152 This trial was conducted to compare the safety profile and efficiency of talazoparib with the protocol-specific physician’s choice (Eribulin, Capecitabine, Vinorelbine or Gemcitabine) in patients with metastatic and/or locally advanced BC. The primary aim of this trial was PFS to identify OS, ORR, and safety as the secondary objectives. The exploratory objective was to evaluate health-related quality of life (HRQ) evaluations DOR. In this trial, the subject eligibility was to involve ≥ 18 years of individuals, cytologically/histologically established metastatic and/or locally advanced BC with gBRCA1/2 mutations, less than or equal to two earlier chemotherapy-inclusive treatments (no frontier on preceding hormonal treatments or targeted anti-tumor treatments, eg mechanistic target of VEGF or monoclonal antibodies against CTL4 or tyrosine kinase inhibitors, CDK4/6 inhibitors, rapamycin (mTOR), or immune-oncology agents),151,152 previous therapies with an anthracycline and/or taxane, and ECOG performance status less than or equal to 1. Phase III subjects (n = 429) will be randomized (2:1) to receive either the physician’s choice therapy or single-agent talazoparib oral capsules (1.0 mg/d, 3 weeks). This clinical trial is currently enrolling participants from Asia, the US, Europe, South America, and Israel.151 The percentage of baseline peripheral blood mononuclear cell (PBMC) activity of PARP was defined as the mean of the early dose PARP activity evaluations during the multiple daily dosing valuation phase, ie, early dose evaluations on days 15, 22, and 35 of cycle one. The mean percentage of baseline PBMC PARP activity with talazoparib (multiple dose levels) has also been documented. It has been indicated that the overall PBMC activity of PARP decreases with the estimated dose limit of talazoparib. Concentration-response and dose-response associations between PMBC, PARP and Talazoparib activities, and the maximum enzyme inhibitory effect model.116 A summary of various clinical trials of talazoparib for BC, OC, and STs is given in Tables 3–5, respectively. Talazoparib in Solid Tumors as a Combination Therapy As previously outlined, talazoparib, a selective PARP inhibitor, has shown increased therapeutic efficacy when used in conjunction with other agents in patients with advanced STs, particularly those harboring BRCA1/2 mutations or other deficiencies in DNA damage response (DDR). A summary of clinical and translational development of talazoparib combination regimens in STs is shown in Table 6. Preclinical studies indicate synergistic effects with immune checkpoint inhibitors, chemotherapy, and targeted therapies, with the aim of overcoming resistance and enhancing outcomes in tumor types such as breast, ovarian, prostate, and NSCLC. Clinical trials have predominantly focused on phase I/II studies to determine safety, dosing, and preliminary efficacy, with ongoing research into biomarker-driven patient selection. Table 6Clinical and Translational Development of Talazoparib Combination Regimens in Solid TumorsCombination StrategyTumor Types StudiedStudy PhaseBiological RationaleKey FindingsReferenceTalazoparib + Avelumab (PD-L1 inhibitor)BRCA1/2- or ATM-altered solid tumors; TNBC; NSCLC; ovarian; mCRPC (NCT03330405)Phase 1b/2 (JAVELIN PARP Medley)PARP inhibition increases DNA damage and neoantigen signaling, enhancing immune responseManageable safety; durable responses in DDR-positive cohorts; activity comparable to PARP monotherapy in some subgroups[128]Talazoparib + Avelumab (DDR-selected population)BRCA1/2- or ATM-altered advanced STs. (NCT03565991)Phase 2b (JAVELIN BRCA/ATM)Synthetic lethality + immune modulation in DDR-deficient tumorsClinical activity observed in BRCA-altered tumors; limited activity in ATM-altered cohorts[127]Talazoparib + TemozolomideRefractory/recurrent pediatric STs (Ewing sarcoma, others) (NCT02116777)Phase 1/2Alkylator-induced DNA damage combined with PARP inhibitionFeasible regimen; hematologic toxicity dose-limiting; modest response rates[132]Talazoparib + enzalutamide (androgen receptor inhibitor)Neuroendocrine prostate cancer (NEPC) PreclinicalIndicated role of glucocorticoid receptor signaling in ENZ-induced and PARP inhibitor-suppressed NEPC.Tumor inhibition in vitro and in vivo[153]Talazoparib + Radiation therapyMultiple solid tumor modelsPreclinical/early translationalPARP inhibition impairs DNA repair following radiationEnhanced radiosensitization and DNA damage accumulation[154] Table 6Clinical and Translational Development of Talazoparib Combination Regimens in Solid TumorsCombination StrategyTumor Types StudiedStudy PhaseBiological RationaleKey FindingsReferenceTalazoparib + Avelumab (PD-L1 inhibitor)BRCA1/2- or ATM-altered solid tumors; TNBC; NSCLC; ovarian; mCRPC (NCT03330405)Phase 1b/2 (JAVELIN PARP Medley)PARP inhibition increases DNA damage and neoantigen signaling, enhancing immune responseManageable safety; durable responses in DDR-positive cohorts; activity comparable to PARP monotherapy in some subgroups[128]Talazoparib + Avelumab (DDR-selected population)BRCA1/2- or ATM-altered advanced STs. (NCT03565991)Phase 2b (JAVELIN BRCA/ATM)Synthetic lethality + immune modulation in DDR-deficient tumorsClinical activity observed in BRCA-altered tumors; limited activity in ATM-altered cohorts[127]Talazoparib + TemozolomideRefractory/recurrent pediatric STs (Ewing sarcoma, others) (NCT02116777)Phase 1/2Alkylator-induced DNA damage combined with PARP inhibitionFeasible regimen; hematologic toxicity dose-limiting; modest response rates[132]Talazoparib + enzalutamide (androgen receptor inhibitor)Neuroendocrine prostate cancer (NEPC) PreclinicalIndicated role of glucocorticoid receptor signaling in ENZ-induced and PARP inhibitor-suppressed NEPC.Tumor inhibition in vitro and in vivo[153]Talazoparib + Radiation therapyMultiple solid tumor modelsPreclinical/early translationalPARP inhibition impairs DNA repair following radiationEnhanced radiosensitization and DNA damage accumulation[154] Clinical and Translational Development of Talazoparib Combination Regimens in Solid Tumors In the JAVELIN PARP Medley trial, the combination of talazoparib (1 mg daily) and avelumab (800 mg biweekly) was assessed using a basket design across multiple solid tumor cohorts. ORRs were significant in BRCA-altered subgroups, including 63.6% in platinum-sensitive, BRCA1/2-altered OC (median duration of response [DOR] not reached; range 5.6 to ≥18.4 months), 34.8% in hormone receptor-positive, DDR-positive BC (median DOR 15.7 months), and 18.2% TNBC (median DOR 11.1 months). Limited activity was observed in non-BRCA DDR-positive tumors, highlighting the importance of BRCA status for response. The regimen was well-tolerated, with common grade 3/4 adverse events including anemia (33.6%), thrombocytopenia (21.5%), and neutropenia (13.9%), leading to dose reductions in 34.5% of patients, primarily due to hematologic toxicities.128 The JAVELIN BRCA/ATM trial further evaluated talazoparib plus avelumab in a tumor-agnostic approach for BRCA1/2- or ATM-altered advanced STs. In the BRCA1/2 cohort (n=159), the confirmed ORR was 26.4% (including 5.7% complete responses), with higher rates (30.3%) in BRCA-associated tumor types such as ovarian, breast, prostate, and pancreatic cancers (median DOR 10.9 months; median PFS 3.7 months). Responses were numerically greater in tumors with high mutational burden (≥10 mut/Mb; ORR 62.5%). However, the ATM cohort exhibited low activity (ORR 4.9%), leading to early discontinuation. Safety was consistent, with grade ≥3 treatment-related adverse events in 49.0% of patients, predominantly anemia (34.0%), thrombocytopenia (15.0%), and neutropenia (11.0%), and no treatment-related deaths. These findings suggest that the combination’s efficacy is largely driven by BRCA1/2 alterations rather than a broad tumor-agnostic benefit.127 The combination with chemotherapy, such as talazoparib plus carboplatin and paclitaxel, has been investigated in a phase I trial (NCI9782) for advanced STs. The recommended phase II dose was talazoparib 250 mcg daily (for 3–7 days per cycle), carboplatin AUC 6, and paclitaxel 80 mg/m², with an ORR of 39.5% (including 3 complete responses) among 38 evaluable patients, particularly in those with DDR alterations like BRCA1/2 or PALB2. The clinical benefit rate was 84.2%, with maintenance talazoparib feasible (median 8 cycles in monotherapy). Myelosuppression was prominent, with grade 3/4 neutropenia in 95% and anemia in 52%, necessitating dose modifications in nearly all patients and supportive care.129 Emerging therapeutic combinations include talazoparib in conjunction with the BET inhibitor ZEN-3694, as investigated in the ongoing phase II ComBET trial (NCT05327010). This trial targets molecularly selected advanced STs characterized by mutations in BRCA1/2, other DNA damage repair (DDR) genes, or KRAS. The primary objective was to assess the ORR according to RECIST v1.1 criteria, while secondary endpoints encompass safety, clinical benefit rate, PFS, and biomarker analyses. Eligibility criteria necessitate the presence of biopsiable lesions and specific genetic profiles, with exclusion of individuals with prior exposure to BET inhibitors. Although preliminary results are yet to be reported, the trial underscores the transition towards precision oncology in the context of talazoparib combinations.155 Chatterjee et al investigated the cellular toxicity of PARP inhibitors, specifically talazoparib and/or olaparib, in oral cancer cells, focusing on the underlying mechanisms, using in vitro, in silico, and in vivo preclinical model systems. In oral cancer cell lines, including the H-357 ‎line, the combination of talazoparib and olaparib, following pretreatment with a DNA-damaging agent (curcumin), resulted in increased apoptosis, elevated levels of the DNA ‎damage marker γH2AX, and greater PARP-trapping compared to either drug alone.156‎ In a separate study, talazoparib combined with quinacrine, a topoisomerase inhibitor, targeted ‎oral mucosa cancer stem cells (OM-CSCs) by modulating the histone acetyltransferases GCN5 and ‎P300. This led to inhibition of chromatin remodeling, increased genomic instability (indicated ‎by γH2AX accumulation), and enhanced apoptosis (up to 43.8% apoptotic cells). This combination demonstrated synergy in patient-derived xenografts, suggesting its potential to eliminate therapy-resistant stem cell populations in oral squamous cell carcinoma (OSCC).157 ‎ Most data on oral cancer are in the preclinical phase (cell lines and xenografts) rather ‎than in large clinical trials. Although talazoparib is a well-established single-agent treatment for certain BRCA/HRR-mutated cancers, its use as a combination therapy in oral cancers remains ‎under investigation. Preclinical data suggest promising synergy when combined with DNA-damaging agents (curcumin, radiation) or other PARP inhibitors, particularly in contexts where ‎DNA damage is induced and the repair capacity is compromised. Although there exists a mechanistic rationale for using talazoparib as a combination therapy in oral cancer (eg, PARP inhibition + radiation or DNA damage in HNSCC),158 specific clinical trials in this area are limited or not publicly available. Considering the biomarker-driven approach, talazoparib shows promise for ‎tumors with underlying DNA repair defects. While BRCA mutations are rare in OSCC, other alterations in the HRD pathway (eg, in genes such as ATM, ATR, ‎and FANCA) are present in some patients, making them potential candidates for this therapy. ‎ Conclusions Cancer remains a formidable global health challenge, with BC and OC contributing significantly to the burden of STs, particularly in individuals harboring germline BRCA1/2 mutations. BRCA1/2 genes play a critical role in DNA double-strand break repair via homologous recombination, and their mutations confer heightened susceptibility to BC and OC, with lifetime risks ranging from 60–85% for BC and 10–54% for OC, depending on the specific gene affected. The discovery of BRCA1 in 1994 and BRCA2 in 1995 marked pivotal milestones in understanding hereditary cancer predisposition, revealing associations with additional malignancies such as prostate, pancreatic, and colorectal cancers. Poly(ADP-ribose) polymerases, particularly PARP1/2, are essential enzymes in single-strand DNA break repair through base excision repair pathways. Inhibition of PARP leads to the accumulation of unrepaired DNA damage, which, in BRCA1/2-deficient cells, exploits synthetic lethality by overwhelming alternative repair mechanisms like non-homologous end-joining, resulting in cell death. This principle has driven the development of PARPi as targeted therapies, evolving from early nicotinamide analogs like 3-aminobenzamide in the 1980s to advanced agents. The discovery journey of PARPi, highlights key FDA approved drugs such as iniparib, olaparib, veliparib, niraparib, rucaparib, and talazoparib, many of which are nicotinamide mimetics that competitively bind PARP’s catalytic domain. Talazoparib stands out for its superior potency (IC50 = 0.57 nM), demonstrating approximately 100-fold greater potency than other PARPi, and its dual mechanism of PARP inhibition and DNA trapping. Its development progressed from preclinical models demonstrating efficacy in BRCA-mutated tumors to clinical trials evaluating monotherapy and combinations. Clinical updates on talazoparib underscore its therapeutic implications across BC, OC, and other STs. Phase 1–3 trials, including EMBRACA (Phase 3) and ABRAZO (Phase 2), have shown improved progression-free survival and overall survival in patients with gBRCA-mutated, HER2-negative advanced BC compared to standard chemotherapy, with manageable safety profiles. Clinical trials like TALAPRO-2 (Phase 3) have explored talazoparib in combination with agents such as enzalutamide, temozolomide, or avelumab, revealing potential to overcome resistance and enhance outcomes in homologous recombination-deficient tumors. Ongoing studies in neoadjuvant settings and other solid malignancies further affirm the versatility of talazoparib. Overall, the advancements in PARP inhibition, exemplified by talazoparib, represent a transformative approach in therapy offering improved clinical outcomes for patients with BRCA1/2-mutated cancers by leveraging synthetic lethality, addressing drug resistance through synergistic combinations, and expanding therapeutic options beyond traditional chemotherapy. These developments highlight the potential to mitigate the global cancer burden, particularly in high-risk populations, through continued integration into clinical practice. All clinically approved PARP inhibitors, including talazoparib, have partial BBB penetration. Therefore, the search for new PARPi continues, and AZD9574 is emerging as a promising candidate. This selective inhibitor has been developed to address challenges related to the BBB, efflux transporters, and subtype selectivity. Drug resistance has become a significant barrier in talazoparib’s clinical application. Future investigations focusing on resistance mechanisms, disease settings, and rational combination regimens with immunotherapy or DNA-damage response inhibitors are likely to broaden talazoparib’s clinical impact in precision oncology. Future clinical research should prioritize solutions to overcome BBB penetration issues and PARPi drug resistance.